haematuria O U-Disease O B-Disease
and O O O O
abdominal B-Disease B-Disease B-Disease B-Disease
aortic I-Disease I-Disease I-Disease I-Disease
aneurysm L-Disease L-Disease I-Disease I-Disease
. O O O O
haematuria O U-Disease O B-Disease
and O O O O
left O B-Disease O B-Disease
loin O I-Disease O I-Disease
pain O L-Disease O I-Disease
in O O O O
a O O O O
patient O O O O
with O O O O
abdominal B-Disease B-Disease B-Disease B-Disease
aortic L-Disease I-Disease I-Disease I-Disease
aneurysm O L-Disease O I-Disease
and O O O O
associated O O O O
with O O O O
the O O O O
radiological O O O O
finding O O O O
of O O O O
a O O O O
poorly O O O O
or O O O O
non O B-Disease O B-Disease
- O I-Disease O I-Disease
functioning O I-Disease O I-Disease
left O I-Disease O I-Disease
kidney O L-Disease O I-Disease
are O O O O
the O O O O
pathognomonic O O O O
features O O O O
of O O O O
aorto O B-Disease O B-Disease
- O I-Disease O I-Disease
left O I-Disease O I-Disease
renal O I-Disease O I-Disease
vein O I-Disease O I-Disease
fistula O L-Disease O I-Disease
, O O O O
a O O O O
condition O O O O
in O O O O
which O O O O
the O O O O
aneurysm O O O O
leaks O O O O
into O O O O
an O O O O
anomalous O O O O
retro O B-Disease O B-Disease
- O I-Disease O I-Disease
aortic O I-Disease O I-Disease
left O I-Disease O I-Disease
renal O I-Disease O I-Disease
vein O L-Disease O I-Disease
. O O O O
acanthosis B-Disease B-Disease B-Disease B-Disease
nigricans L-Disease L-Disease I-Disease I-Disease
. O O O O
acanthosis B-Disease B-Disease B-Disease B-Disease
nigricans L-Disease L-Disease I-Disease I-Disease
is O O O O
thickened O O O O
, O O O O
velvety O U-Disease O B-Disease
, O O O O
hyperpigmented O B-Disease O B-Disease
skin O L-Disease O I-Disease
associated O O O O
with O O O O
a O O O O
variety O O O O
of O O O O
endocrine B-Disease B-Disease B-Disease B-Disease
disorders L-Disease L-Disease I-Disease I-Disease
, O O O O
malignancies U-Disease U-Disease B-Disease B-Disease
and O O O O
medications O O O O
. O O O O
the O O O O
mechanical O O O O
stability O O O O
of O O O O
internal O B-Disease O B-Disease
fixation O I-Disease O I-Disease
of O I-Disease O I-Disease
fractured B-Disease I-Disease B-Disease I-Disease
phalanges L-Disease L-Disease I-Disease I-Disease
. O O O O
the O O O O
rigidity O O O O
of O O O O
five O O O O
techniques O O O O
of O O O O
internal O B-Disease O B-Disease
fixation O I-Disease O I-Disease
of O I-Disease O I-Disease
fractured B-Disease I-Disease B-Disease I-Disease
phalanges L-Disease L-Disease I-Disease I-Disease
is O O O O
tested O O O O
experimentally O O O O
and O O O O
compared O O O O
. O O O O
the O O O O
clinical O O O O
relevance O O O O
is O O O O
discussed O O O O
. O O O O
renal B-Disease B-Disease B-Disease B-Disease
cell I-Disease I-Disease I-Disease I-Disease
carcinoma L-Disease L-Disease I-Disease I-Disease
with O O O O
concurrent O O O O
urothelial B-Disease B-Disease B-Disease B-Disease
carcinoma L-Disease L-Disease I-Disease I-Disease
of O O O O
urinary O B-Disease O B-Disease
bladder O I-Disease O I-Disease
and O I-Disease O I-Disease
non B-Disease I-Disease B-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
hodgkin I-Disease I-Disease I-Disease I-Disease
lymphoma L-Disease L-Disease I-Disease I-Disease
. O O O O
we O O O O
report O O O O
a O O O O
case O O O O
of O O O O
a O O O O
00 O O O O
- O O O O
year O O O O
- O O O O
old O O O O
male O O O O
with O O O O
multiple O O O O
primary O B-Disease O B-Disease
malignancies U-Disease L-Disease B-Disease I-Disease
involving O O O O
kidney O B-Disease O B-Disease
and O I-Disease O I-Disease
urinary O I-Disease O I-Disease
bladder O L-Disease O I-Disease
, O O O O
combined O O O O
with O O O O
synchronous O B-Disease O B-Disease
lymphoma U-Disease L-Disease B-Disease I-Disease
. O O O O
the O O O O
patient O O O O
was O O O O
admitted O O O O
to O O O O
the O O O O
hospital O O O O
because O O O O
of O O O O
painless O B-Disease O B-Disease
gross O I-Disease O I-Disease
hematuria U-Disease L-Disease B-Disease I-Disease
. O O O O
examination O O O O
revealed O O O O
tumor U-Disease B-Disease B-Disease B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
right O I-Disease O I-Disease
kidney O I-Disease O I-Disease
and O I-Disease O I-Disease
papillary U-Disease I-Disease B-Disease I-Disease
tumor O I-Disease O I-Disease
in O I-Disease O I-Disease
the O I-Disease O I-Disease
urinary O I-Disease O I-Disease
bladder O I-Disease O I-Disease
and O I-Disease O I-Disease
enlarged O I-Disease O I-Disease
lymph O I-Disease O I-Disease
nodes O L-Disease O I-Disease
along O O O O
aorta O B-Disease O B-Disease
and O I-Disease O I-Disease
inferior O I-Disease O I-Disease
vena O I-Disease O I-Disease
cava O L-Disease O I-Disease
. O O O O
transurethral O O O O
resection O O O O
of O O O O
bladder B-Disease B-Disease B-Disease B-Disease
tumor L-Disease L-Disease I-Disease I-Disease
( O O O O
tur O U-Disease O B-Disease
) O O O O
, O O O O
radical O B-Disease O B-Disease
nephrectomy O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
right O I-Disease O I-Disease
kidney O I-Disease O I-Disease
and O I-Disease O I-Disease
retroperitoneal O I-Disease O I-Disease
lymphadenectomy O L-Disease O I-Disease
were O O O O
performed O O O O
. O O O O
pathohistologic O O O O
evaluation O O O O
, O O O O
together O O O O
with O O O O
immunohistochemistry O O O O
, O O O O
gave O O O O
the O O O O
patient O O O O
the O O O O
final O O O O
diagnosis O O O O
of O O O O
renal B-Disease B-Disease B-Disease B-Disease
cell I-Disease I-Disease I-Disease I-Disease
carcinoma L-Disease L-Disease I-Disease I-Disease
( O O O O
rcc U-Disease U-Disease B-Disease B-Disease
) O O O O
, O O O O
urothelial B-Disease B-Disease B-Disease B-Disease
carcinoma L-Disease I-Disease I-Disease I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
urinary O I-Disease O I-Disease
bladder O I-Disease O I-Disease
and O I-Disease O I-Disease
b B-Disease I-Disease B-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
small I-Disease I-Disease I-Disease I-Disease
cell I-Disease I-Disease I-Disease I-Disease
non I-Disease I-Disease I-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
hodgkin I-Disease I-Disease I-Disease I-Disease
lymphoma L-Disease L-Disease I-Disease I-Disease
( O O O O
b B-Disease B-Disease B-Disease B-Disease
- I-Disease I-Disease I-Disease I-Disease
cll L-Disease L-Disease I-Disease I-Disease
) O O O O
. O O O O
scanning O O O O
electron O O O O
microscopy O O O O
of O O O O
the O O O O
human O O O O
zonule O O O O
of O O O O
the O O O O
lens O O O O
( O O O O
zonula O O O O
ciliaris O O O O
) O O O O
. O O O O
in O O O O
the O O O O
present O O O O
study O O O O
eight O O O O
human O O O O
eyeballs O O O O
were O O O O
specifically O O O O
prepared O O O O
for O O O O
scanning O O O O
- O O O O
electron O O O O
- O O O O
microscopic O O O O
observation O O O O
of O O O O
the O O O O
zonule O O O O
. O O O O
the O O O O
zonule O O O O
consisted O O O O
of O O O O
two O O O O
main O O O O
layers O O O O
of O O O O
radial O O O O
fibres O O O O
, O O O O
an O O O O
anterior O O O O
and O O O O
a O O O O
posterior O O O O
one O O O O
, O O O O
that O O O O
inserted O O O O
on O O O O
the O O O O
anterior O B-Disease O B-Disease
and O I-Disease O I-Disease
the O I-Disease O I-Disease
posterior O I-Disease O I-Disease
lens O L-Disease O I-Disease
capsules O O O O
, O O O O
respectively O O O O
. O O O O
some O O O O
fibres O O O O
inserted O O O O
on O O O O
the O O O O
equator O O O O
of O O O O
the O O O O
lens O O O O
. O O O O
posterior O O O O
zonular O O O O
fibres O O O O
originated O O O O
at O O O O
the O O O O
pars O B-Disease O B-Disease
plana O L-Disease O I-Disease
, O O O O
entered O O O O
the O O O O
dorsal O O O O
part O O O O
of O O O O
the O O O O
ciliary O O O O
valleys O O O O
and O O O O
then O O O O
changed O O O O
their O O O O
direction O O O O
towards O O O O
the O O O O
posterior O B-Disease O B-Disease
face O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
lens O L-Disease O I-Disease
. O O O O
posterior O O O O
fibres O O O O
inserted O O O O
on O O O O
the O O O O
posterior O B-Disease O B-Disease
capsule O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
lens O L-Disease O I-Disease
by O O O O
branched O O O O
endings O O O O
0 O O O O
mm O O O O
behind O O O O
the O O O O
equator O O O O
of O O O O
the O O O O
lens O O O O
. O O O O
anterior O O O O
zonular O O O O
fibres O O O O
originated O O O O
mainly O O O O
at O O O O
the O O O O
pars O B-Disease O B-Disease
plana O L-Disease O I-Disease
and O O O O
occasionally O O O O
at O O O O
the O O O O
ciliary O O O O
valleys O O O O
. O O O O
after O O O O
running O O O O
completely O O O O
through O O O O
the O O O O
ciliary O O O O
valleys O O O O
in O O O O
close O O O O
contact O O O O
with O O O O
the O O O O
lateral O O O O
walls O O O O
of O O O O
the O O O O
ciliary O O O O
processes O O O O
, O O O O
they O O O O
changed O O O O
their O O O O
direction O O O O
at O O O O
the O O O O
anterior O B-Disease O B-Disease
endings O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
pars O I-Disease O I-Disease
plicata O L-Disease O I-Disease
and O O O O
reached O O O O
the O O O O
anterior O B-Disease O B-Disease
lens O I-Disease O I-Disease
capsule O L-Disease O I-Disease
. O O O O
anterior O O O O
zonular O O O O
insertions O O O O
were O O O O
achieved O O O O
by O O O O
webbed O O O O
endings O O O O
that O O O O
diffused O O O O
into O O O O
the O O O O
anterior O O O O
capsule O O O O
0 O O O O
mm O O O O
in O O O O
front O O O O
of O O O O
the O O O O
lens O O O O
equator O O O O
. O O O O
the O O O O
extraordinary O O O O
distension O O O O
capacity O O O O
of O O O O
the O O O O
zonular O O O O
fibres O O O O
was O O O O
demonstrated O O O O
by O O O O
pulling O O O O
the O O O O
anterior O B-Disease O B-Disease
lens O I-Disease O I-Disease
capsule O L-Disease O I-Disease
after O O O O
hydrodissection O O O O
. O O O O
as O O O O
a O O O O
consequence O O O O
, O O O O
the O O O O
anterior O O O O
fibres O O O O
were O O O O
stretched O O O O
up O O O O
to O O O O
four O O O O
times O O O O
their O O O O
original O O O O
length O O O O
without O O O O
breaking O O O O
or O O O O
<OOV> O O O O
. O O O O
sonographic O O O O
<OOV> O O O O
after O O O O
nephrectomy O O O O
. O O O O
when O O O O
interpreting O O O O
renal O B-Disease O B-Disease
sonograms O L-Disease O I-Disease
, O O O O
one O O O O
should O O O O
be O O O O
aware O O O O
of O O O O
the O O O O
possibility O O O O
of O O O O
mistaking O B-Disease O B-Disease
fat O L-Disease O I-Disease
and O O O O
scarring O B-Disease O B-Disease
in O I-Disease O I-Disease
the O I-Disease O I-Disease
renal O I-Disease O I-Disease
fossa O L-Disease O I-Disease
for O O O O
a O O O O
normal O O O O
kidney O O O O
in O O O O
a O O O O
patient O O O O
with O O O O
a O O O O
history O O O O
of O O O O
prior O O O O
nephrectomy O O O O
. O O O O
when O O O O
in O O O O
doubt O O O O
, O O O O
the O O O O
ultrasound O O O O
findings O O O O
should O O O O
be O O O O
confirmed O O O O
with O O O O
a O O O O
ct O O O O
scan O O O O
. O O O O
color O O O O
pattern O O O O
- O O O O
reversal O O O O
visual O O O O
evoked O O O O
potential O O O O
in O O O O
eyes O O O O
with O O O O
ocular B-Disease O B-Disease O
hypertension L-Disease U-Disease I-Disease B-Disease
and O O O O
primary B-Disease B-Disease B-Disease B-Disease
open I-Disease I-Disease I-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
angle I-Disease I-Disease I-Disease I-Disease
glaucoma L-Disease L-Disease I-Disease I-Disease
. O O O O
color O O O O
pattern O O O O
- O O O O
reversal O O O O
visual O O O O
evoked O O O O
potential O O O O
testing O O O O
was O O O O
performed O O O O
in O O O O
00 O O O O
normal O O O O
eyes O O O O
, O O O O
00 O O O O
eyes O O O O
with O O O O
ocular B-Disease O B-Disease O
hypertension L-Disease U-Disease I-Disease B-Disease
and O O O O
00 O O O O
eyes O O O O
with O O O O
primary O B-Disease O B-Disease
open B-Disease I-Disease B-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
angle I-Disease I-Disease I-Disease I-Disease
glaucoma L-Disease L-Disease I-Disease I-Disease
with O O O O
the O O O O
use O O O O
of O O O O
black O O O O
- O O O O
white O O O O
, O O O O
black O O O O
- O O O O
red O O O O
and O O O O
black O O O O
- O O O O
blue O O O O
color O O O O
checkerboard O O O O
stimuli O O O O
. O O O O
the O O O O
p0 O O O O
wave O O O O
peak O O O O
time O O O O
and O O O O
amplitude O O O O
of O O O O
the O O O O
eyes O O O O
with O O O O
ocular B-Disease O B-Disease O
hypertension L-Disease U-Disease I-Disease B-Disease
and O O O O
glaucoma U-Disease U-Disease B-Disease B-Disease
were O O O O
significantly O O O O
different O O O O
from O O O O
those O O O O
of O O O O
age O O O O
- O O O O
similar O O O O
normal O O O O
eyes O O O O
, O O O O
especially O O O O
on O O O O
the O O O O
black O O O O
- O O O O
red O O O O
and O O O O
black O O O O
- O O O O
blue O O O O
checkerboards O O O O
( O O O O
p O O O O
less O O O O
than O O O O
0 O O O O
. O O O O
000 O O O O
) O O O O
. O O O O
the O O O O
differences O O O O
between O O O O
the O O O O
ocular O O O O
hypertensive O U-Disease O B-Disease
and O O O O
glaucomatous O O O O
eyes O O O O
were O O O O
of O O O O
less O O O O
significance O O O O
. O O O O
the O O O O
p0 O O O O
peak O O O O
time O O O O
difference O O O O
between O O O O
black O O O O
- O O O O
white O O O O
and O O O O
black O O O O
- O O O O
red O O O O
checkerboards O O O O
may O O O O
serve O O O O
as O O O O
an O O O O
important O O O O
parameter O O O O
in O O O O
the O O O O
early O O O O
diagnosis O O O O
of O O O O
glaucoma U-Disease U-Disease B-Disease B-Disease
. O O O O
comparison O O O O
of O O O O
secretory O O O O
iga O O O O
and O O O O
igg O O O O
isotype O O O O
levels O O O O
in O O O O
palatal O B-Disease O B-Disease
secretions O I-Disease O I-Disease
of O I-Disease O I-Disease
denture B-Disease I-Disease B-Disease I-Disease
stomatitis L-Disease L-Disease I-Disease I-Disease
patients O O O O
with O O O O
denture O B-Disease O B-Disease
wearers O L-Disease O I-Disease
having O O O O
clinically O O O O
healthy O O O O
palates O U-Disease O B-Disease
. O O O O
denture B-Disease O B-Disease O
stomatitis L-Disease U-Disease I-Disease B-Disease
is O O O O
an O O O O
inflammatory B-Disease B-Disease B-Disease B-Disease
condition L-Disease L-Disease I-Disease I-Disease
affecting O O O O
palatal O B-Disease O B-Disease
mucosa O L-Disease O I-Disease
covered O O O O
by O O O O
a O O O O
denture O O O O
. O O O O
aetiology O O O O
is O O O O
multifactorial O O O O
involving O O O O
poor O O O O
hygiene O O O O
, O O O O
constant O O O O
denture O B-Disease O B-Disease
wearing O L-Disease O I-Disease
, O O O O
trauma U-Disease U-Disease B-Disease B-Disease
and O O O O
colonisation O O O O
by O O O O
candida O O O O
species O O O O
. O O O O
in O O O O
inflamed O O O O
tissues O O O O
raised O O O O
levels O O O O
of O O O O
albumin O O O O
, O O O O
igg O O O O
isotypes O O O O
and O O O O
secretory O O O O
iga O O O O
( O O O O
siga O O O O
) O O O O
would O O O O
be O O O O
expected O O O O
. O O O O
siga O O O O
is O O O O
a O O O O
major O O O O
component O O O O
of O O O O
the O O O O
protective O O O O
immunological O O O O
response O O O O
to O O O O
mucosal O B-Disease O B-Disease
injection O I-Disease O I-Disease
. O I-Disease O I-Disease
palatal O I-Disease O I-Disease
secretions O L-Disease O I-Disease
of O O O O
00 O O O O
patients O O O O
with O O O O
denture B-Disease B-Disease B-Disease B-Disease
stomatitis L-Disease L-Disease I-Disease I-Disease
and O O O O
00 O O O O
denture O B-Disease O B-Disease
wearing O L-Disease O I-Disease
patients O O O O
with O O O O
clinically O O O O
healthy O O O O
palates O O O O
were O O O O
analysed O O O O
for O O O O
albumin O O O O
, O O O O
igg O O O O
isotypes O O O O
and O O O O
siga O O O O
levels O O O O
. O O O O
albumin O O O O
and O O O O
igg O O O O
isotype O O O O
levels O O O O
were O O O O
found O O O O
to O O O O
be O O O O
higher O O O O
in O O O O
denture B-Disease O B-Disease O
stomatitis L-Disease U-Disease I-Disease B-Disease
patients O O O O
compared O O O O
with O O O O
healthy O B-Disease O B-Disease
palate O L-Disease O I-Disease
patients O O O O
. O O O O
unexpectedly O O O O
, O O O O
siga O O O O
levels O O O O
were O O O O
found O O O O
to O O O O
be O O O O
significantly O O O O
( O O O O
p O O O O
< O O O O
0 O O O O
. O O O O
00 O O O O
) O O O O
lower O O O O
in O O O O
denture B-Disease O B-Disease O
stomatitis L-Disease U-Disease I-Disease B-Disease
patients O O O O
compared O O O O
with O O O O
healthy O B-Disease O B-Disease
palate O L-Disease O I-Disease
patients O O O O
. O O O O
percutaneous O O O O
mechanical O O O O
support O O O O
for O O O O
the O O O O
failing O O O O
right O O O O
heart O O O O
. O O O O
right B-Disease O B-Disease O
ventricular I-Disease B-Disease I-Disease B-Disease
( I-Disease I-Disease I-Disease I-Disease
rv I-Disease I-Disease I-Disease I-Disease
) I-Disease I-Disease I-Disease I-Disease
failure L-Disease L-Disease I-Disease I-Disease
is O O O O
an O O O O
increasingly O O O O
common O O O O
clinical O O O O
problem O O O O
that O O O O
may O O O O
require O O O O
mechanical O O O O
support O O O O
. O O O O
in O O O O
contrast O O O O
to O O O O
severe O O O O
left B-Disease O B-Disease O
ventricular I-Disease B-Disease I-Disease B-Disease
failure L-Disease L-Disease I-Disease I-Disease
, O O O O
rv B-Disease B-Disease B-Disease B-Disease
failure L-Disease L-Disease I-Disease I-Disease
is O O O O
typically O O O O
more O O O O
reversible O O O O
. O O O O
therefore O O O O
, O O O O
application O O O O
of O O O O
shorter O O O O
- O O O O
term O O O O
percutaneous O O O O
support O O O O
devices O O O O
is O O O O
potentially O O O O
attractive O O O O
. O O O O
current O O O O
innovations O O O O
promise O O O O
greater O O O O
availability O O O O
of O O O O
such O O O O
percutaneous O O O O
rv O O O O
support O O O O
devices O O O O
. O O O O
this O O O O
article O O O O
considers O O O O
the O O O O
available O O O O
mechanical O O O O
approaches O O O O
to O O O O
provide O O O O
hemodynamic O O O O
support O O O O
to O O O O
treat O O O O
profound O O O O
rv B-Disease B-Disease B-Disease B-Disease
failure L-Disease L-Disease I-Disease I-Disease
in O O O O
the O O O O
common O O O O
clinical O O O O
scenarios O O O O
in O O O O
which O O O O
percutaneous O O O O
mechanical O O O O
rv O O O O
support O O O O
may O O O O
be O O O O
most O O O O
beneficial O O O O
. O O O O
tetralogy B-Disease O B-Disease O
of I-Disease O I-Disease O
fallot I-Disease U-Disease I-Disease B-Disease
with I-Disease O I-Disease O
<OOV> I-Disease B-Disease I-Disease B-Disease
cardinal I-Disease I-Disease I-Disease I-Disease
vein L-Disease L-Disease I-Disease I-Disease
. O O O O
a O O O O
<OOV> B-Disease O B-Disease O
cardinal I-Disease B-Disease I-Disease B-Disease
vein L-Disease L-Disease I-Disease I-Disease
is O O O O
a O O O O
rare O O O O
congenital B-Disease B-Disease B-Disease B-Disease
anomaly I-Disease I-Disease I-Disease I-Disease
of I-Disease I-Disease I-Disease I-Disease
the I-Disease I-Disease I-Disease I-Disease
systemic I-Disease I-Disease I-Disease I-Disease
veins L-Disease L-Disease I-Disease I-Disease
. O O O O
it O O O O
is O O O O
frequently O O O O
associated O O O O
with O O O O
left B-Disease B-Disease B-Disease B-Disease
- I-Disease I-Disease I-Disease I-Disease
side I-Disease I-Disease I-Disease I-Disease
obstructive I-Disease I-Disease I-Disease I-Disease
anomalies L-Disease L-Disease I-Disease I-Disease
. O O O O
we O O O O
report O O O O
a O O O O
case O O O O
of O O O O
tetralogy B-Disease B-Disease B-Disease B-Disease
of I-Disease I-Disease I-Disease I-Disease
fallot L-Disease L-Disease I-Disease I-Disease
with O O O O
a O O O O
<OOV> B-Disease B-Disease B-Disease B-Disease
cardinal I-Disease I-Disease I-Disease I-Disease
vein L-Disease L-Disease I-Disease I-Disease
. O O O O
the O O O O
innominate O B-Disease O B-Disease
vein O L-Disease O I-Disease
was O O O O
absent O O O O
and O O O O
two O O O O
left O O O O
upper O O O O
pulmonary O B-Disease O B-Disease
veins O L-Disease O I-Disease
connected O O O O
to O O O O
this O O O O
vein O O O O
. O O O O
there O O O O
were O O O O
no O O O O
left O O O O
- O O O O
side O O O O
obstructive B-Disease B-Disease B-Disease B-Disease
anomalies L-Disease L-Disease I-Disease I-Disease
. O O O O
aortic O B-Disease O B-Disease
root O I-Disease O I-Disease
replacement O L-Disease O I-Disease
in O O O O
cardiac B-Disease B-Disease B-Disease B-Disease
dextroversion L-Disease L-Disease I-Disease I-Disease
. O O O O
adult O O O O
cardiac O O O O
surgery O O O O
in O O O O
patients O O O O
with O O O O
malrotation B-Disease B-Disease B-Disease B-Disease
of I-Disease I-Disease I-Disease I-Disease
the I-Disease I-Disease I-Disease I-Disease
heart L-Disease L-Disease I-Disease I-Disease
is O O O O
rare O O O O
. O O O O
a O O O O
00 O O O O
year O O O O
- O O O O
old O O O O
lady O O O O
, O O O O
with O O O O
known O O O O
cardiac B-Disease B-Disease B-Disease B-Disease
dextroversion L-Disease L-Disease I-Disease I-Disease
, O O O O
presented O O O O
with O O O O
dyspnoea O U-Disease O B-Disease
and O O O O
pre O B-Disease O B-Disease
- O I-Disease O I-Disease
syncopal O I-Disease O I-Disease
attacks O L-Disease O I-Disease
. O O O O
echocardiographical O O O O
and O O O O
radiological O O O O
investigation O O O O
confirmed O O O O
the O O O O
dextroversion U-Disease O B-Disease O
, O O O O
with O O O O
clockwise O O O O
rotation O O O O
of O O O O
the O O O O
heart O O O O
through O O O O
its O O O O
longitudinal O O O O
axis O O O O
. O O O O
this O O O O
resulted O O O O
in O O O O
the O O O O
right O O O O
ventricular O B-Disease O B-Disease
outflow O I-Disease O I-Disease
tract O L-Disease O I-Disease
and O O O O
pulmonary O B-Disease O B-Disease
artery O L-Disease O I-Disease
being O O O O
wrapped O O O O
anteriorly O O O O
around O O O O
the O O O O
aorta O O O O
, O O O O
with O O O O
posterior O B-Disease O B-Disease
displacement O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
right O I-Disease O I-Disease
atrium O L-Disease O I-Disease
. O O O O
the O O O O
presence O O O O
of O O O O
a O O O O
heavily O O O O
calcified O O O O
, O O O O
bicuspid B-Disease B-Disease B-Disease B-Disease
aortic I-Disease I-Disease I-Disease I-Disease
valve L-Disease L-Disease I-Disease I-Disease
and O O O O
dilated O B-Disease O B-Disease
ascending O I-Disease O I-Disease
aorta O L-Disease O I-Disease
was O O O O
also O O O O
demonstrated O O O O
. O O O O
at O O O O
surgery O O O O
, O O O O
venous O B-Disease O B-Disease
cannulation O L-Disease O I-Disease
was O O O O
established O O O O
by O O O O
rotating O O O O
the O O O O
heart O O O O
anticlockwise O O O O
and O O O O
access O O O O
to O O O O
the O O O O
aortic O B-Disease O B-Disease
valve O L-Disease O I-Disease
gained O O O O
with O O O O
a O O O O
more O O O O
superior O O O O
oblique O O O O
aortotomy O O O O
. O O O O
in O O O O
the O O O O
presence O O O O
of O O O O
a O O O O
dilated O B-Disease O B-Disease
ascending O I-Disease O I-Disease
aorta O L-Disease O I-Disease
with O O O O
a O O O O
calcified O O O O
, O O O O
bicuspid B-Disease B-Disease B-Disease B-Disease
aortic I-Disease I-Disease I-Disease I-Disease
valve L-Disease L-Disease I-Disease I-Disease
, O O O O
the O O O O
aortic O O O O
root O O O O
was O O O O
replaced O O O O
with O O O O
a O O O O
valved O O O O
conduit O O O O
. O O O O
to O O O O
the O O O O
authors O O O O
' O O O O
knowledge O O O O
, O O O O
this O O O O
is O O O O
the O O O O
first O O O O
report O O O O
of O O O O
an O O O O
aortic O B-Disease O B-Disease
root O I-Disease O I-Disease
replacement O L-Disease O I-Disease
in O O O O
a O O O O
patient O O O O
with O O O O
cardiac B-Disease B-Disease B-Disease B-Disease
dextroversion L-Disease L-Disease I-Disease I-Disease
. O O O O
iatrogenic O O O O
cyanosis O U-Disease O B-Disease
and O O O O
clubbing O U-Disease O B-Disease
: O O O O
00 O O O O
years O O O O
of O O O O
chronic O B-Disease O B-Disease
hypoxia U-Disease L-Disease B-Disease I-Disease
after O O O O
the O O O O
repair O O O O
of O O O O
an O O O O
atrial B-Disease B-Disease B-Disease B-Disease
septal I-Disease I-Disease I-Disease I-Disease
defect L-Disease L-Disease I-Disease I-Disease
. O O O O
a O O O O
case O O O O
of O O O O
sinus O B-Disease O B-Disease
venosus O I-Disease O I-Disease
atrial B-Disease I-Disease B-Disease I-Disease
septal I-Disease I-Disease I-Disease I-Disease
defect L-Disease I-Disease I-Disease I-Disease
repair O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
inferior O I-Disease O I-Disease
vena O I-Disease O I-Disease
caval O I-Disease O I-Disease
type O L-Disease O I-Disease
with O O O O
an O O O O
unintentional O O O O
diversion O B-Disease O B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
inferior O I-Disease O I-Disease
vena O L-Disease O I-Disease
caval O O O O
blood O O O O
to O O O O
the O O O O
left O O O O
atrium O O O O
is O O O O
reported O O O O
. O O O O
long O O O O
- O O O O
standing O O O O
, O O O O
anatomical O O O O
, O O O O
right O O O O
- O O O O
to O O O O
- O O O O
left O B-Disease O B-Disease
shunting O L-Disease O I-Disease
with O O O O
cyanosis O U-Disease O B-Disease
and O O O O
hypoxia U-Disease U-Disease B-Disease B-Disease
are O O O O
associated O O O O
with O O O O
systemic O U-Disease O B-Disease
and O O O O
cerebrovascular B-Disease B-Disease B-Disease B-Disease
complications L-Disease L-Disease I-Disease I-Disease
. O O O O
cardiac O O O O
risks O O O O
depend O O O O
on O O O O
the O O O O
presence O O O O
or O O O O
absence O O O O
of O O O O
pulmonary B-Disease B-Disease B-Disease B-Disease
hypertension L-Disease L-Disease I-Disease I-Disease
, O O O O
the O O O O
associated O O O O
hematological B-Disease B-Disease B-Disease B-Disease
abnormalities L-Disease L-Disease I-Disease I-Disease
and O O O O
the O O O O
degree O O O O
of O O O O
anatomical O O O O
, O O O O
right O B-Disease O B-Disease
- O I-Disease O I-Disease
to O I-Disease O I-Disease
- O I-Disease O I-Disease
left O I-Disease O I-Disease
shunting O L-Disease O I-Disease
. O O O O
cardiac O O O O
magnetic O O O O
resonance O O O O
imaging O O O O
clarified O O O O
the O O O O
etiology O O O O
of O O O O
the O O O O
unexplained O B-Disease O B-Disease
cyanosis O L-Disease O I-Disease
and O O O O
delineated O O O O
the O O O O
surgical O O O O
anatomy O O O O
. O O O O
radioimmunoassay O O O O
of O O O O
immunoreactive O O O O
c O O O O
- O O O O
terminal O O O O
big O O O O
- O O O O
endothelin O O O O
( O O O O
00 O O O O
- O O O O
00 O O O O
) O O O O
. O O O O
endothelin O O O O
, O O O O
a O O O O
potent O O O O
endogenous O O O O
vaso O O O O
- O O O O
constrictor O O O O
, O O O O
is O O O O
derived O O O O
from O O O O
its O O O O
biosynthetic O O O O
precursor O O O O
by O O O O
proteolytic O O O O
degradation O O O O
. O O O O
the O O O O
last O O O O
step O O O O
cleaves O O O O
big O O O O
- O O O O
endothelin O O O O
( O O O O
0 O O O O
- O O O O
00 O O O O
) O O O O
to O O O O
endothelin O O O O
( O O O O
0 O O O O
- O O O O
00 O O O O
) O O O O
and O O O O
a O O O O
c O O O O
- O O O O
terminal O O O O
fragment O O O O
. O O O O
we O O O O
have O O O O
developed O O O O
a O O O O
radioimmunoassay O O O O
for O O O O
this O O O O
peptide O O O O
, O O O O
based O O O O
on O O O O
an O O O O
antiserum O O O O
recognizing O O O O
the O O O O
c O O O O
- O O O O
terminal O O O O
sequence O O O O
big O O O O
- O O O O
endothelin O O O O
( O O O O
00 O O O O
- O O O O
00 O O O O
) O O O O
and O O O O
cross O O O O
- O O O O
reacting O O O O
with O O O O
intact O O O O
big O O O O
- O O O O
endothelin O O O O
. O O O O
to O O O O
test O O O O
for O O O O
the O O O O
presence O O O O
of O O O O
immunoreactive O O O O
big O O O O
- O O O O
endothelin O O O O
( O O O O
00 O O O O
- O O O O
00 O O O O
) O O O O
in O O O O
plasma O O O O
, O O O O
samples O O O O
were O O O O
extracted O O O O
by O O O O
passage O O O O
through O O O O
<OOV> O O O O
silica O O O O
cartridges O O O O
, O O O O
and O O O O
desorption O O O O
with O O O O
methanol O O O O
/ O O O O
water O O O O
volume O O O O
fraction O O O O
0 O O O O
. O O O O
0 O O O O
. O O O O
the O O O O
yields O O O O
of O O O O
this O O O O
purification O O O O
and O O O O
concentration O O O O
procedure O O O O
were O O O O
about O O O O
00 O O O O
% O O O O
. O O O O
in O O O O
00 O O O O
healthy O O O O
persons O O O O
we O O O O
found O O O O
concentrations O O O O
of O O O O
0 O O O O
- O O O O
00 O O O O
pmol O O O O
/ O O O O
l O O O O
, O O O O
which O O O O
is O O O O
about O O O O
00 O O O O
- O O O O
fold O O O O
higher O O O O
than O O O O
the O O O O
reference O O O O
levels O O O O
reported O O O O
for O O O O
endothelin O O O O
( O O O O
0 O O O O
- O O O O
00 O O O O
) O O O O
or O O O O
big O O O O
- O O O O
endothelin O O O O
( O O O O
0 O O O O
- O O O O
00 O O O O
) O O O O
. O O O O
thus O O O O
, O O O O
endothelin O O O O
- O O O O
derived O O O O
peptides O O O O
containing O O O O
the O O O O
big O O O O
- O O O O
endothelin O O O O
( O O O O
00 O O O O
- O O O O
00 O O O O
) O O O O
sequence O O O O
, O O O O
but O O O O
different O O O O
from O O O O
intact O O O O
big O O O O
- O O O O
endothelin O O O O
, O O O O
do O O O O
circulate O O O O
in O O O O
human O O O O
blood O O O O
. O O O O
if O O O O
a O O O O
sufficiently O O O O
tight O O O O
correlation O O O O
to O O O O
levels O O O O
of O O O O
circulating O O O O
endothelin O O O O
( O O O O
0 O O O O
- O O O O
00 O O O O
) O O O O
can O O O O
be O O O O
proven O O O O
, O O O O
this O O O O
would O O O O
facilitate O O O O
studies O O O O
on O O O O
the O O O O
physiological O O O O
role O O O O
of O O O O
endogenous O O O O
endothelin O O O O
. O O O O
visualization O O O O
of O O O O
the O O O O
heterogeneous O O O O
membrane O O O O
distribution O O O O
of O O O O
sphingomyelin O O O O
associated O O O O
with O O O O
cytokinesis O O O O
, O O O O
cell O O O O
polarity O O O O
, O O O O
and O O O O
<OOV> U-Disease O B-Disease O
. O O O O
sphingomyelin O O O O
( O O O O
sm O O O O
) O O O O
is O O O O
a O O O O
major O O O O
sphingolipid O O O O
in O O O O
mammalian O O O O
cells O O O O
and O O O O
is O O O O
reported O O O O
to O O O O
form O O O O
specific O O O O
lipid O O O O
domains O O O O
together O O O O
with O O O O
cholesterol O O O O
. O O O O
however O O O O
, O O O O
methods O O O O
to O O O O
examine O O O O
the O O O O
membrane O O O O
distribution O O O O
of O O O O
sm O U-Disease O B-Disease
are O O O O
limited O O O O
. O O O O
we O O O O
demonstrated O O O O
in O O O O
model O O O O
membranes O O O O
that O O O O
fluorescent O O O O
protein O O O O
conjugates O O O O
of O O O O
0 O O O O
specific O O O O
sm O O O O
- O O O O
binding O O O O
toxins O O O O
, O O O O
lysenin O O O O
( O O O O
lys O O O O
) O O O O
and O O O O
equinatoxin O O O O
ii O O O O
( O O O O
<OOV> O O O O
) O O O O
, O O O O
recognize O O O O
different O O O O
membrane O O O O
distributions O O O O
of O O O O
sm O O O O
; O O O O
lys O O O O
exclusively O O O O
binds O O O O
clustered O O O O
sm O O O O
, O O O O
whereas O O O O
<OOV> O O O O
preferentially O O O O
binds O O O O
dispersed O O O O
sm O O O O
. O O O O
freeze O O O O
- O O O O
fracture O O O O
immunoelectron O O O O
microscopy O O O O
showed O O O O
that O O O O
clustered O O O O
but O O O O
not O O O O
dispersed O O O O
sm O O O O
formed O O O O
lipid O O O O
domains O O O O
on O O O O
the O O O O
cell O O O O
surface O O O O
. O O O O
glycolipids O O O O
and O O O O
the O O O O
membrane O O O O
concentration O O O O
of O O O O
sm O O O O
affect O O O O
the O O O O
sm O O O O
distribution O O O O
pattern O O O O
on O O O O
the O O O O
plasma O O O O
membrane O O O O
. O O O O
using O O O O
derivatives O O O O
of O O O O
lys O O O O
and O O O O
<OOV> O O O O
as O O O O
sm O O O O
distribution O O O O
- O O O O
sensitive O O O O
probes O O O O
, O O O O
we O O O O
revealed O O O O
the O O O O
exclusive O O O O
accumulation O O O O
of O O O O
sm O O O O
clusters O O O O
in O O O O
the O O O O
midbody O O O O
at O O O O
the O O O O
time O O O O
of O O O O
cytokinesis O O O O
. O O O O
interestingly O O O O
, O O O O
apical O O O O
membranes O O O O
of O O O O
differentiated O O O O
epithelial O O O O
cells O O O O
exhibited O O O O
dispersed O O O O
sm O O O O
distribution O O O O
, O O O O
whereas O O O O
sm O O O O
was O O O O
clustered O O O O
in O O O O
basolateral O O O O
membranes O O O O
. O O O O
clustered O O O O
but O O O O
not O O O O
dispersed O O O O
sm O O O O
was O O O O
absent O O O O
from O O O O
the O O O O
cell O O O O
surface O O O O
of O O O O
acid O O O O
sphingomyelinase O O O O
- O O O O
deficient O O O O
niemann B-Disease O B-Disease O
- I-Disease O I-Disease O
pick I-Disease O I-Disease O
type I-Disease O I-Disease O
a L-Disease O I-Disease O
cells O O O O
. O O O O
these O O O O
data O O O O
suggest O O O O
that O O O O
both O O O O
the O O O O
sm O O O O
content O O O O
and O O O O
membrane O O O O
distribution O O O O
are O O O O
crucial O O O O
for O O O O
pathophysiological O O O O
events O O O O
bringing O O O O
therapeutic O O O O
perspective O O O O
in O O O O
the O O O O
role O O O O
of O O O O
sm O O O O
membrane O O O O
distribution O O O O
. O O O O
- O O O O
makino O O O O
, O O O O
a O O O O
. O O O O
, O O O O
abe O O O O
, O O O O
m O O O O
. O O O O
, O O O O
<OOV> O O O O
, O O O O
m O O O O
. O O O O
, O O O O
inaba O O O O
, O O O O
t O O O O
. O O O O
, O O O O
<OOV> O O O O
, O O O O
n O O O O
. O O O O
, O O O O
<OOV> O O O O
- O O O O
matsuda O O O O
, O O O O
f O O O O
. O O O O
, O O O O
<OOV> O O O O
, O O O O
t O O O O
. O O O O
, O O O O
<OOV> O O O O
, O O O O
n O O O O
. O O O O
l O O O O
. O O O O
, O O O O
taguchi O O O O
, O O O O
t O O O O
. O O O O
, O O O O
arai O O O O
, O O O O
h O O O O
. O O O O
, O O O O
<OOV> O O O O
, O O O O
g O O O O
. O O O O
, O O O O
parton O O O O
, O O O O
r O O O O
. O O O O
g O O O O
. O O O O
, O O O O
kobayashi O O O O
, O O O O
t O O O O
. O O O O
visualization O O O O
of O O O O
the O O O O
heterogeneous O O O O
membrane O O O O
distribution O O O O
of O O O O
sphingomyelin O O O O
associated O O O O
with O O O O
cytokinesis O O O O
, O O O O
cell O O O O
polarity O O O O
, O O O O
and O O O O
<OOV> U-Disease O B-Disease O
. O O O O
improvement O O O O
of O O O O
eeg O O O O
signal O O O O
acquisition O O O O
: O O O O
an O O O O
electrical O O O O
aspect O O O O
for O O O O
state O O O O
of O O O O
the O O O O
art O O O O
of O O O O
front O O O O
end O O O O
. O O O O
the O O O O
aim O O O O
of O O O O
this O O O O
study O O O O
is O O O O
to O O O O
present O O O O
some O O O O
practical O O O O
state O O O O
- O O O O
of O O O O
- O O O O
the O O O O
- O O O O
art O O O O
considerations O O O O
in O O O O
acquiring O O O O
satisfactory O O O O
signals O O O O
for O O O O
electroencephalographic O O O O
signal O O O O
acquisition O O O O
. O O O O
these O O O O
considerations O O O O
are O O O O
important O O O O
for O O O O
users O O O O
and O O O O
system O O O O
designers O O O O
. O O O O
especially O O O O
choosing O O O O
correct O O O O
electrode O O O O
and O O O O
design O O O O
strategy O O O O
of O O O O
the O O O O
initial O O O O
electronic O O O O
circuitry O O O O
front O O O O
end O O O O
plays O O O O
an O O O O
important O O O O
role O O O O
in O O O O
improving O O O O
the O O O O
system O O O O
' O O O O
s O O O O
measurement O O O O
performance O O O O
. O O O O
considering O O O O
the O O O O
pitfalls O O O O
in O O O O
the O O O O
design O O O O
of O O O O
biopotential O O O O
measurement O O O O
system O O O O
and O O O O
recording O O O O
session O O O O
conditions O O O O
creates O O O O
better O O O O
accuracy O O O O
. O O O O
in O O O O
electroencephalogram O O O O
( O O O O
eeg O O O O
) O O O O
recording O O O O
electrodes O O O O
, O O O O
system O O O O
electronics O O O O
including O O O O
filtering O O O O
, O O O O
amplifying O O O O
, O O O O
signal O O O O
conversion O O O O
, O O O O
data O O O O
storing O O O O
, O O O O
and O O O O
environmental O O O O
conditions O O O O
affect O O O O
the O O O O
recording O O O O
performance O O O O
. O O O O
in O O O O
this O O O O
paper O O O O
, O O O O
eeg O O O O
electrode O O O O
principles O O O O
and O O O O
main O O O O
points O O O O
of O O O O
electronic O O O O
noise O O O O
reduction O O O O
methods O O O O
in O O O O
eeg O O O O
signal O O O O
acquisition O O O O
front O O O O
end O O O O
are O O O O
discussed O O O O
, O O O O
and O O O O
some O O O O
suggestions O O O O
for O O O O
improving O O O O
signal O O O O
acquisition O O O O
are O O O O
presented O O O O
. O O O O
comparative O O O O
in O O O O
vitro O O O O
activity O O O O
of O O O O
the O O O O
new O O O O
oral O O O O
cephalosporin O O O O
bmy O O O O
- O O O O
<OOV> O O O O
. O O O O
using O O O O
a O O O O
broth O O O O
microdilution O O O O
method O O O O
, O O O O
the O O O O
in O O O O
vitro O O O O
activity O O O O
of O O O O
bmy O O O O
- O O O O
<OOV> O O O O
against O O O O
000 O O O O
clinical O O O O
strains O O O O
of O O O O
commonly O O O O
isolated O O O O
bacteria O O O O
was O O O O
determined O O O O
. O O O O
bmy O O O O
- O O O O
<OOV> O O O O
showed O O O O
good O O O O
activity O O O O
against O O O O
streptococci O O O O
, O O O O
methicillin O O O O
- O O O O
susceptible O O O O
staphylococci O O O O
, O O O O
salmonella O O O O
spp O O O O
. O O O O
, O O O O
shigella O O O O
spp O O O O
. O O O O
, O O O O
and O O O O
beta O O O O
- O O O O
lactamase O O O O
producing O O O O
branhamella O O O O
catarrhalis O O O O
and O O O O
haemophilus O O O O
influenzae O O O O
. O O O O
against O O O O
susceptible O O O O
strains O O O O
of O O O O
these O O O O
organisms O O O O
, O O O O
bmy O O O O
- O O O O
<OOV> O O O O
showed O O O O
activity O O O O
comparable O O O O
to O O O O
that O O O O
of O O O O
penicillin O O O O
g O O O O
, O O O O
ampicillin O O O O
, O O O O
co O O O O
- O O O O
<OOV> O O O O
, O O O O
erythromycin O O O O
, O O O O
cefaclor O O O O
, O O O O
doxycycline O O O O
and O O O O
amoxicillin O O O O
/ O O O O
potassium O O O O
clavulanate O O O O
. O O O O
bmy O O O O
- O O O O
<OOV> O O O O
had O O O O
moderate O O O O
activity O O O O
against O O O O
arizona O O O O
<OOV> O O O O
and O O O O
poor O O O O
activity O O O O
against O O O O
campylobacter O O O O
jejuni O O O O
and O O O O
yersinia O O O O
enterocolitica O O O O
. O O O O
reimplantation O O O O
of O O O O
the O O O O
dilated O O O O
ectopic O O O O
ureter O O O O
of O O O O
the O O O O
duplex O O O O
system O O O O
as O O O O
a O O O O
separate O O O O
unit O O O O
. O O O O
separate O O O O
reimplantation O O O O
of O O O O
the O O O O
dilated O O O O
ureter O O O O
provided O O O O
a O O O O
surgical O O O O
alternative O O O O
in O O O O
0 O O O O
patients O O O O
with O O O O
duplex B-Disease B-Disease B-Disease B-Disease
ureters L-Disease L-Disease I-Disease I-Disease
, O O O O
in O O O O
whom O O O O
ureteroureterostomy O O O O
or O O O O
double O O O O
reimplantation O O O O
might O O O O
have O O O O
compromised O O O O
the O O O O
smaller O O O O
caliber O B-Disease O B-Disease
normal O I-Disease O I-Disease
ureter O L-Disease O I-Disease
. O O O O
folliculitis U-Disease U-Disease B-Disease B-Disease
, O O O O
follicular B-Disease B-Disease B-Disease B-Disease
mucinosis L-Disease L-Disease I-Disease I-Disease
, O O O O
and O O O O
papular B-Disease B-Disease B-Disease B-Disease
mucinosis L-Disease L-Disease I-Disease I-Disease
as O O O O
a O O O O
presentation O O O O
of O O O O
chronic B-Disease B-Disease B-Disease B-Disease
myelomonocytic I-Disease I-Disease I-Disease I-Disease
leukemia L-Disease L-Disease I-Disease I-Disease
. O O O O
leukemias U-Disease U-Disease B-Disease B-Disease
and O O O O
lymphomas U-Disease U-Disease B-Disease B-Disease
can O O O O
present O O O O
in O O O O
indolent O O O O
and O O O O
surprisingly O O O O
unusual O O O O
manners O O O O
. O O O O
although O O O O
uncommon O O O O
, O O O O
follicular B-Disease B-Disease B-Disease B-Disease
lesions L-Disease L-Disease I-Disease I-Disease
such O O O O
as O O O O
eosinophilic B-Disease B-Disease B-Disease B-Disease
folliculitis L-Disease L-Disease I-Disease I-Disease
have O O O O
been O O O O
reported O O O O
in O O O O
association O O O O
with O O O O
leukemia U-Disease U-Disease B-Disease B-Disease
. O O O O
however O O O O
, O O O O
follicular O B-Disease O B-Disease
and O I-Disease O I-Disease
papular B-Disease I-Disease B-Disease I-Disease
mucinosis L-Disease L-Disease I-Disease I-Disease
are O O O O
novel O O O O
associations O O O O
for O O O O
chronic B-Disease B-Disease B-Disease B-Disease
myelomonocytic I-Disease I-Disease I-Disease I-Disease
leukemia L-Disease L-Disease I-Disease I-Disease
. O O O O
acute B-Disease O B-Disease O
straight I-Disease O I-Disease O
lateral I-Disease B-Disease I-Disease B-Disease
instability I-Disease I-Disease I-Disease I-Disease
of I-Disease I-Disease I-Disease I-Disease
the I-Disease I-Disease I-Disease I-Disease
knee L-Disease L-Disease I-Disease I-Disease
. O O O O
although O O O O
ligamentous O B-Disease O B-Disease
injuries O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
knee O I-Disease O I-Disease
joint O L-Disease O I-Disease
represent O O O O
a O O O O
common O O O O
orthopaedic O O O O
problem O O O O
, O O O O
damage O O O O
to O O O O
the O O O O
lateral O O O O
supporting O O O O
structures O O O O
is O O O O
a O O O O
relatively O O O O
rare O O O O
occurrence O O O O
. O O O O
osteosarcoma U-Disease U-Disease B-Disease B-Disease
of O O O O
medial O B-Disease O B-Disease
<OOV> O I-Disease O I-Disease
bone O L-Disease O I-Disease
. O O O O
osteosarcoma U-Disease U-Disease B-Disease B-Disease
is O O O O
most O O O O
common O O O O
primary O B-Disease O B-Disease
bone B-Disease I-Disease B-Disease I-Disease
malignancy L-Disease L-Disease I-Disease I-Disease
of O O O O
childhood O O O O
and O O O O
adolescent O O O O
that O O O O
is O O O O
not O O O O
related O O O O
to O O O O
marrow O O O O
cells O O O O
. O O O O
osteosarcoma U-Disease U-Disease B-Disease B-Disease
usually O O O O
occurs O O O O
at O O O O
the O O O O
end O O O O
of O O O O
long O O O O
bones O O O O
commonly O O O O
around O O O O
the O O O O
knee O B-Disease O B-Disease
joint O I-Disease O I-Disease
. O I-Disease O I-Disease
osteosarcoma U-Disease I-Disease B-Disease I-Disease
of O I-Disease O I-Disease
small O I-Disease O I-Disease
bones O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
foot O L-Disease O I-Disease
is O O O O
very O O O O
rare O O O O
. O O O O
here O O O O
i O O O O
tried O O O O
to O O O O
present O O O O
osteosarcoma U-Disease B-Disease B-Disease B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
medial O I-Disease O I-Disease
cuneiform O I-Disease O I-Disease
bone O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
foot O L-Disease O I-Disease
in O O O O
00 O O O O
years O O O O
old O O O O
male O O O O
patient O O O O
. O O O O
responding O O O O
to O O O O
evidence O O O O
: O O O O
breastfeed O O O O
baby O O O O
if O O O O
you O O O O
can O O O O
- O O O O
- O O O O
the O O O O
sixth O O O O
public O O O O
health O O O O
recommendation O O O O
to O O O O
reduce O O O O
the O O O O
risk O O O O
of O O O O
sudden B-Disease B-Disease B-Disease B-Disease
and I-Disease I-Disease I-Disease I-Disease
unexpected I-Disease I-Disease I-Disease I-Disease
death L-Disease L-Disease I-Disease I-Disease
in O O O O
infancy O O O O
. O O O O
abundant O O O O
evidence O O O O
recognises O O O O
breastfeeding O O O O
as O O O O
being O O O O
associated O O O O
with O O O O
significant O O O O
short O O O O
and O O O O
long O O O O
- O O O O
term O O O O
health O O O O
benefits O O O O
for O O O O
both O O O O
infant O O O O
and O O O O
mother O O O O
. O O O O
until O O O O
recently O O O O
, O O O O
the O O O O
role O O O O
of O O O O
breastfeeding O O O O
as O O O O
an O O O O
independent O O O O
factor O O O O
in O O O O
reducing O O O O
risk O O O O
for O O O O
sudden O B-Disease O B-Disease
unexpected O I-Disease O I-Disease
infant B-Disease I-Disease B-Disease I-Disease
death L-Disease L-Disease I-Disease I-Disease
remained O O O O
unclear O O O O
. O O O O
in O O O O
october O O O O
0000 O O O O
, O O O O
sids U-Disease O B-Disease O
and O O O O
kids O O O O
australia O O O O
held O O O O
a O O O O
consensus O O O O
forum O O O O
with O O O O
international O O O O
researchers O O O O
and O O O O
key O O O O
stakeholders O O O O
to O O O O
review O O O O
current O O O O
evidence O O O O
relating O O O O
to O O O O
safe O O O O
infant O O O O
sleeping O O O O
recommendations O O O O
. O O O O
following O O O O
this O O O O
forum O O O O
and O O O O
the O O O O
publication O O O O
of O O O O
key O O O O
reviews O O O O
, O O O O
the O O O O
sids U-Disease U-Disease B-Disease B-Disease
and O O O O
kids O O O O
national O O O O
scientific O O O O
advisory O O O O
group O O O O
has O O O O
supported O O O O
the O O O O
decision O O O O
that O O O O
a O O O O
critical O O O O
threshold O O O O
had O O O O
been O O O O
reached O O O O
within O O O O
the O O O O
evidence O O O O
that O O O O
is O O O O
supportive O O O O
of O O O O
breastfeeding O O O O
as O O O O
a O O O O
specific O O O O
risk O O O O
reduction O O O O
measure O O O O
for O O O O
sudden B-Disease B-Disease B-Disease B-Disease
unexpected I-Disease I-Disease I-Disease I-Disease
death L-Disease L-Disease I-Disease I-Disease
in O O O O
infancy O O O O
. O O O O
a O O O O
sixth O O O O
recommendation O O O O
, O O O O
breastfeed O O O O
baby O O O O
if O O O O
you O O O O
can O O O O
, O O O O
will O O O O
be O O O O
included O O O O
in O O O O
the O O O O
0000 O O O O
sids U-Disease U-Disease B-Disease B-Disease
and O O O O
kids O O O O
safe O O O O
sleeping O O O O
national O O O O
public O O O O
health O O O O
campaign O O O O
. O O O O
abusive O O O O
head B-Disease B-Disease B-Disease B-Disease
trauma L-Disease L-Disease I-Disease I-Disease
in O O O O
infants O O O O
and O O O O
young O O O O
children O O O O
: O O O O
a O O O O
unique O O O O
contributor O O O O
to O O O O
developmental B-Disease B-Disease B-Disease B-Disease
disabilities L-Disease L-Disease I-Disease I-Disease
. O O O O
abusive O O O O
head B-Disease B-Disease B-Disease B-Disease
trauma L-Disease L-Disease I-Disease I-Disease
in O O O O
infants O O O O
and O O O O
young O O O O
children O O O O
is O O O O
the O O O O
leading O O O O
cause O O O O
of O O O O
death U-Disease U-Disease B-Disease B-Disease
and O O O O
disability O O O O
from O O O O
child B-Disease O B-Disease O
abuse L-Disease O I-Disease O
. O O O O
this O O O O
article O O O O
discusses O O O O
the O O O O
history O O O O
, O O O O
epidemiology O O O O
, O O O O
clinical O O O O
aspects O O O O
, O O O O
developmental O O O O
outcomes O O O O
, O O O O
and O O O O
associated O O O O
injuries O O O O
of O O O O
this O O O O
unique O O O O
contributor O O O O
to O O O O
developmental B-Disease B-Disease B-Disease B-Disease
disabilities L-Disease L-Disease I-Disease I-Disease
. O O O O
prevention O O O O
of O O O O
abusive B-Disease O B-Disease O
injuries L-Disease O I-Disease O
and O O O O
prevention O O O O
of O O O O
child O O O O
abuse O O O O
and O O O O
neglect O U-Disease O B-Disease
are O O O O
also O O O O
discussed O O O O
. O O O O
longitudinal O O O O
osteotomy O B-Disease O B-Disease
of O I-Disease O I-Disease
lateral O I-Disease O I-Disease
sacrum O L-Disease O I-Disease
for O O O O
malignant O B-Disease O B-Disease
iliac B-Disease I-Disease B-Disease I-Disease
tumor L-Disease L-Disease I-Disease I-Disease
using O O O O
modified O O O O
<OOV> O O O O
saw O O O O
. O O O O
a O O O O
longitudinal O B-Disease O B-Disease
osteotomy O I-Disease O I-Disease
of O I-Disease O I-Disease
lateral O I-Disease O I-Disease
sacrum O L-Disease O I-Disease
for O O O O
malignant O B-Disease O B-Disease
iliac B-Disease I-Disease B-Disease I-Disease
tumors L-Disease L-Disease I-Disease I-Disease
using O O O O
modified O O O O
<OOV> O O O O
saw O O O O
is O O O O
conducted O O O O
. O O O O
this O O O O
procedure O O O O
<OOV> O O O O
wide O O O O
, O O O O
rapid O O O O
and O O O O
safe O O O O
. O O O O
septic B-Disease O B-Disease O
arthritis L-Disease B-Disease I-Disease B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
hip O L-Disease O I-Disease
in O O O O
children O O O O
. O O O O
early O O O O
diagnosis O O O O
of O O O O
septic B-Disease B-Disease B-Disease B-Disease
arthritis L-Disease L-Disease I-Disease I-Disease
of O O O O
the O O O O
hip O U-Disease O B-Disease
is O O O O
important O O O O
as O O O O
a O O O O
delay O O O O
in O O O O
treatment O O O O
may O O O O
lead O O O O
to O O O O
permanent O B-Disease O B-Disease
damage O L-Disease O I-Disease
and O O O O
disability O B-Disease O B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
hip O L-Disease O I-Disease
. O O O O
however O O O O
, O O O O
this O O O O
may O O O O
be O O O O
difficult O O O O
, O O O O
especially O O O O
in O O O O
young O O O O
children O O O O
. O O O O
the O O O O
clinical O O O O
presentation O O O O
. O O O O
investigation O O O O
and O O O O
management O O O O
of O O O O
septic B-Disease B-Disease B-Disease B-Disease
arthritis L-Disease L-Disease I-Disease I-Disease
of O O O O
the O O O O
hip O U-Disease O B-Disease
is O O O O
reviewed O O O O
. O O O O
a O O O O
short O O O O
- O O O O
term O O O O
epidemiological O O O O
study O O O O
of O O O O
median B-Disease O B-Disease O
nerve I-Disease B-Disease I-Disease B-Disease
dysfunction L-Disease L-Disease I-Disease I-Disease
in O O O O
practicing O O O O
dental O O O O
hygienists O O O O
. O O O O
the O O O O
purpose O O O O
of O O O O
this O O O O
study O O O O
was O O O O
to O O O O
assess O O O O
over O O O O
time O O O O
changes O O O O
in O O O O
median O O O O
nerve O O O O
function O O O O
in O O O O
a O O O O
group O O O O
of O O O O
00 O O O O
students O O O O
who O O O O
entered O O O O
the O O O O
university O O O O
of O O O O
minnesota O O O O
dental O O O O
hygiene O O O O
program O O O O
in O O O O
0000 O O O O
. O O O O
this O O O O
is O O O O
a O O O O
follow O O O O
- O O O O
up O O O O
report O O O O
on O O O O
00 O O O O
of O O O O
the O O O O
00 O O O O
students O O O O
who O O O O
were O O O O
evaluated O O O O
two O O O O
years O O O O
postgraduation O O O O
in O O O O
0000 O O O O
. O O O O
comparisons O O O O
were O O O O
made O O O O
with O O O O
prior O O O O
evaluations O O O O
of O O O O
the O O O O
subjects O O O O
completed O O O O
at O O O O
graduation O O O O
in O O O O
0000 O O O O
, O O O O
and O O O O
one O O O O
year O O O O
postgraduation O O O O
in O O O O
0000 O O O O
. O O O O
digital O O O O
vibrometry O O O O
was O O O O
used O O O O
to O O O O
evaluate O O O O
median O O O O
nerve O O O O
sensibility O O O O
threshold O O O O
at O O O O
each O O O O
of O O O O
the O O O O
time O O O O
periods O O O O
studied O O O O
. O O O O
analysis O O O O
revealed O O O O
that O O O O
after O O O O
one O O O O
year O O O O
of O O O O
clinical O O O O
practice O O O O
, O O O O
there O O O O
was O O O O
a O O O O
mean O O O O
sensibility O O O O
threshold O O O O
shift O O O O
of O O O O
00 O O O O
. O O O O
00 O O O O
% O O O O
in O O O O
the O O O O
left O O O O
median O O O O
nerve O O O O
and O O O O
0 O O O O
. O O O O
00 O O O O
% O O O O
in O O O O
the O O O O
right O O O O
median O O O O
nerve O O O O
as O O O O
measured O O O O
by O O O O
digital O O O O
vibrometry O O O O
. O O O O
results O O O O
at O O O O
two O O O O
years O O O O
postgraduation O O O O
indicated O O O O
that O O O O
the O O O O
threshold O O O O
shift O O O O
observed O O O O
in O O O O
an O O O O
earlier O O O O
study O O O O
had O O O O
been O O O O
arrested O O O O
. O O O O
the O O O O
reasons O O O O
appeared O O O O
to O O O O
be O O O O
twofold O O O O
: O O O O
( O O O O
0 O O O O
) O O O O
a O O O O
period O O O O
of O O O O
work O O O O
hardening O O O O
with O O O O
a O O O O
concept O O O O
of O O O O
neuromuscular O B-Disease O B-Disease
ligamentous O I-Disease O I-Disease
tissue O I-Disease O I-Disease
hypertrophy O L-Disease O I-Disease
or O O O O
adaptation O O O O
to O O O O
the O O O O
rigors O O O O
of O O O O
dental O O O O
hygiene O O O O
practice O O O O
, O O O O
and O O O O
/ O O O O
or O O O O
( O O O O
0 O O O O
) O O O O
the O O O O
practicing O O O O
dental O O O O
hygienist O O O O
had O O O O
learned O O O O
to O O O O
become O O O O
more O O O O
efficient O O O O
in O O O O
the O O O O
provision O O O O
of O O O O
hygiene O O O O
procedures O O O O
. O O O O
there O O O O
were O O O O
no O O O O
reported O O O O
symptoms O O O O
of O O O O
median B-Disease O B-Disease O
nerve I-Disease B-Disease I-Disease B-Disease
dysfunction L-Disease L-Disease I-Disease I-Disease
and O O O O
none O O O O
of O O O O
the O O O O
subjects O O O O
had O O O O
been O O O O
diagnosed O O O O
as O O O O
having O O O O
cts U-Disease U-Disease B-Disease B-Disease
at O O O O
any O O O O
time O O O O
during O O O O
the O O O O
two O O O O
years O O O O
since O O O O
graduation O O O O
. O O O O
continued O O O O
evaluations O O O O
will O O O O
be O O O O
necessary O O O O
to O O O O
determine O O O O
whether O O O O
the O O O O
observations O O O O
noted O O O O
during O O O O
the O O O O
second O O O O
year O O O O
postgraduation O O O O
evaluation O O O O
indicated O O O O
temporary O O O O
or O O O O
permanent O O O O
slowing O O O O
of O O O O
the O O O O
conditions O O O O
necessary O O O O
for O O O O
the O O O O
development O O O O
of O O O O
cts U-Disease U-Disease B-Disease B-Disease
. O O O O
split O O O O
intrarenal O B-Disease O B-Disease
hemodynamics O L-Disease O I-Disease
in O O O O
renovascular B-Disease B-Disease B-Disease B-Disease
hypertension L-Disease L-Disease I-Disease I-Disease
. O O O O
split O O O O
intrarenal O B-Disease O B-Disease
hemodynamics O L-Disease O I-Disease
in O O O O
stenotic O B-Disease O B-Disease
and O I-Disease O I-Disease
contralateral O I-Disease O I-Disease
kidneys O L-Disease O I-Disease
of O O O O
unilateral O B-Disease O B-Disease
renovascular B-Disease I-Disease B-Disease I-Disease
hypertension L-Disease L-Disease I-Disease I-Disease
( O O O O
rvh U-Disease U-Disease B-Disease B-Disease
) O O O O
were O O O O
estimated O O O O
by O O O O
gomez O O O O
' O O O O
s O O O O
formulae O O O O
. O O O O
ten O O O O
patients O O O O
with O O O O
rvh U-Disease U-Disease B-Disease B-Disease
were O O O O
studied O O O O
. O O O O
split O O O O
para O O O O
- O O O O
amino O O O O
hippurate O O O O
and O O O O
inulin O O O O
clearances O O O O
were O O O O
measured O O O O
by O O O O
ureteral O O O O
catheterization O O O O
as O O O O
indexes O O O O
for O O O O
renal O O O O
plasma O O O O
flow O O O O
and O O O O
glomerular O O O O
filtration O O O O
rates O O O O
, O O O O
allowing O O O O
the O O O O
estimation O O O O
of O O O O
intrarenal O B-Disease O B-Disease
hemodynamics O L-Disease O I-Disease
such O O O O
as O O O O
preglomerular O B-Disease O B-Disease
arteriolar O I-Disease O I-Disease
resistance O L-Disease O I-Disease
, O O O O
postglomerular O O O O
arteriolar O O O O
resistance O O O O
and O O O O
glomerular O O O O
hydrostatic O O O O
pressure O O O O
in O O O O
each O O O O
kidney O O O O
. O O O O
renal O O O O
plasma O O O O
flow O O O O
and O O O O
glomerular O O O O
filtration O O O O
rates O O O O
were O O O O
lower O O O O
in O O O O
the O O O O
stenotic O O O O
kidney O O O O
( O O O O
00 O O O O
+ O O O O
/ O O O O
- O O O O
00 O O O O
, O O O O
00 O O O O
+ O O O O
/ O O O O
- O O O O
0 O O O O
ml O O O O
/ O O O O
min O O O O
/ O O O O
m0 O O O O
) O O O O
than O O O O
in O O O O
the O O O O
contralateral O O O O
kidney O O O O
( O O O O
000 O O O O
+ O O O O
/ O O O O
- O O O O
00 O O O O
, O O O O
00 O O O O
+ O O O O
/ O O O O
- O O O O
0 O O O O
) O O O O
. O O O O
preglomerular O O O O
arteriolar O O O O
resistance O O O O
was O O O O
elevated O O O O
due O O O O
to O O O O
the O O O O
stenotic O O O O
lesion O O O O
in O O O O
the O O O O
stenotic O O O O
kidney O O O O
( O O O O
00 O O O O
, O O O O
000 O O O O
+ O O O O
/ O O O O
- O O O O
0 O O O O
, O O O O
000 O O O O
<OOV> O O O O
. O O O O
sec O O O O
. O O O O
cm O O O O
- O O O O
0 O O O O
) O O O O
while O O O O
the O O O O
elevation O O O O
in O O O O
the O O O O
contralateral O O O O
kidney O O O O
( O O O O
00 O O O O
, O O O O
000 O O O O
+ O O O O
/ O O O O
- O O O O
0 O O O O
, O O O O
000 O O O O
) O O O O
was O O O O
less O O O O
. O O O O
postglomerular O O O O
arteriolar O O O O
resistance O O O O
was O O O O
high O O O O
in O O O O
both O O O O
kidneys O O O O
. O O O O
glomerular O O O O
pressure O O O O
was O O O O
lowered O O O O
in O O O O
the O O O O
stenotic O O O O
kidney O O O O
( O O O O
00 O O O O
+ O O O O
/ O O O O
- O O O O
0 O O O O
mmhg O O O O
) O O O O
, O O O O
while O O O O
elevated O O O O
in O O O O
the O O O O
contralateral O O O O
kidney O O O O
( O O O O
00 O O O O
+ O O O O
/ O O O O
- O O O O
0 O O O O
) O O O O
. O O O O
although O O O O
the O O O O
stenotic O O O O
kidney O O O O
of O O O O
rvh U-Disease U-Disease B-Disease B-Disease
was O O O O
protected O O O O
from O O O O
systemic O B-Disease O B-Disease
hypertension U-Disease L-Disease B-Disease I-Disease
( O O O O
000 O O O O
+ O O O O
/ O O O O
- O O O O
0 O O O O
mmhg O O O O
) O O O O
by O O O O
stenosis B-Disease O B-Disease O
of I-Disease O I-Disease O
the I-Disease O I-Disease O
renal I-Disease B-Disease I-Disease B-Disease
artery L-Disease L-Disease I-Disease I-Disease
, O O O O
the O O O O
increase O O O O
in O O O O
preglomerular O O O O
arteriolar O O O O
resistance O O O O
in O O O O
the O O O O
contralateral O O O O
kidney O O O O
was O O O O
not O O O O
sufficient O O O O
, O O O O
making O O O O
glomerular O O O O
pressure O O O O
elevated O O O O
. O O O O
thus O O O O
, O O O O
glomerular O B-Disease O B-Disease
hypertension O L-Disease O I-Disease
and O O O O
hyperfiltration O U-Disease O B-Disease
were O O O O
demonstrated O O O O
in O O O O
the O O O O
contralateral O O O O
kidney O O O O
of O O O O
rvh U-Disease U-Disease B-Disease B-Disease
. O O O O
paget B-Disease B-Disease B-Disease B-Disease
' I-Disease I-Disease I-Disease I-Disease
s I-Disease I-Disease I-Disease I-Disease
disease L-Disease L-Disease I-Disease I-Disease
complicated O O O O
by O O O O
hydrocephalus U-Disease U-Disease B-Disease B-Disease
and O O O O
syringomyelia U-Disease U-Disease B-Disease B-Disease
. O O O O
the O O O O
authors O O O O
report O O O O
a O O O O
case O O O O
of O O O O
paget B-Disease B-Disease B-Disease B-Disease
' I-Disease I-Disease I-Disease I-Disease
s I-Disease I-Disease I-Disease I-Disease
disease L-Disease L-Disease I-Disease I-Disease
involving O O O O
the O O O O
skull O O O O
with O O O O
the O O O O
rare O O O O
but O O O O
severe O O O O
complications O O O O
of O O O O
hydrocephalus U-Disease U-Disease B-Disease B-Disease
and O O O O
syringomyelia U-Disease U-Disease B-Disease B-Disease
related O O O O
to O O O O
basilar O B-Disease O B-Disease
impression O L-Disease O I-Disease
. O O O O
complications O O O O
of O O O O
paget B-Disease B-Disease B-Disease B-Disease
' I-Disease I-Disease I-Disease I-Disease
s I-Disease I-Disease I-Disease I-Disease
disease L-Disease I-Disease I-Disease I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
skull O L-Disease O I-Disease
are O O O O
briefly O O O O
discussed O O O O
and O O O O
current O O O O
treatment O O O O
strategies O O O O
outlined O O O O
. O O O O
hemiplegia B-Disease B-Disease B-Disease B-Disease
<OOV> I-Disease I-Disease I-Disease I-Disease
<OOV> L-Disease L-Disease I-Disease I-Disease
( O O O O
ipsilateral B-Disease B-Disease B-Disease B-Disease
horner I-Disease I-Disease I-Disease I-Disease
' I-Disease I-Disease I-Disease I-Disease
s I-Disease I-Disease I-Disease I-Disease
syndrome L-Disease L-Disease I-Disease I-Disease
and O O O O
contralateral B-Disease B-Disease B-Disease B-Disease
<OOV> L-Disease L-Disease I-Disease I-Disease
) O O O O
following O O O O
proximal O B-Disease O B-Disease
posterior O I-Disease O I-Disease
cerebral B-Disease I-Disease B-Disease I-Disease
artery I-Disease I-Disease I-Disease I-Disease
occlusion L-Disease L-Disease I-Disease I-Disease
. O O O O
background O O O O
: O O O O
posterior B-Disease B-Disease B-Disease B-Disease
cerebral I-Disease I-Disease I-Disease I-Disease
artery I-Disease L-Disease I-Disease I-Disease
( I-Disease O I-Disease O
pca I-Disease U-Disease I-Disease B-Disease
) I-Disease O I-Disease O
occlusive I-Disease B-Disease I-Disease B-Disease
disease L-Disease L-Disease I-Disease I-Disease
usually O O O O
produces O O O O
homonymous O B-Disease O B-Disease
visual O I-Disease O I-Disease
field O I-Disease O I-Disease
defects O L-Disease O I-Disease
, O O O O
hemisensory O B-Disease O B-Disease
loss O L-Disease O I-Disease
, O O O O
and O O O O
neuropsychological O B-Disease O B-Disease
deficits O L-Disease O I-Disease
. O O O O
conversely O O O O
, O O O O
the O O O O
combination O O O O
of O O O O
hemiparesis O U-Disease O B-Disease
, O O O O
horner O B-Disease O B-Disease
' O I-Disease O I-Disease
s O I-Disease O I-Disease
syndrome O L-Disease O I-Disease
, O O O O
and O O O O
contralateral O B-Disease O B-Disease
<OOV> O L-Disease O I-Disease
has O O O O
never O O O O
been O O O O
reported O O O O
before O O O O
. O O O O
case O O O O
description O O O O
: O O O O
a O O O O
patient O O O O
with O O O O
infarction O B-Disease O B-Disease
in O I-Disease O I-Disease
the O I-Disease O I-Disease
superficial O I-Disease O I-Disease
and O I-Disease O I-Disease
deep O I-Disease O I-Disease
territories O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
right O I-Disease O I-Disease
pca O L-Disease O I-Disease
presented O O O O
with O O O O
a O O O O
unique O O O O
clinical O O O O
picture O O O O
, O O O O
which O O O O
included O O O O
contralateral O B-Disease O B-Disease
hemiparesis O L-Disease O I-Disease
, O O O O
<OOV> O U-Disease O B-Disease
, O O O O
and O O O O
ipsilateral O B-Disease O B-Disease
horner O I-Disease O I-Disease
' O I-Disease O I-Disease
s O I-Disease O I-Disease
syndrome O L-Disease O I-Disease
. O O O O
magnetic O O O O
resonance O O O O
imaging O O O O
disclosed O O O O
infarcts O B-Disease O B-Disease
in O I-Disease O I-Disease
the O I-Disease O I-Disease
right O I-Disease O I-Disease
anterolateral O I-Disease O I-Disease
midbrain O L-Disease O I-Disease
, O O O O
ventroposterolateral O O O O
thalamic O B-Disease O B-Disease
- O I-Disease O I-Disease
subthalamic O I-Disease O I-Disease
area O L-Disease O I-Disease
, O O O O
and O O O O
<OOV> O B-Disease O B-Disease
- O I-Disease O I-Disease
occipital O I-Disease O I-Disease
lobes O L-Disease O I-Disease
. O O O O
conclusions O O O O
: O O O O
the O O O O
alternating O B-Disease O B-Disease
vegetative O I-Disease O I-Disease
syndrome O L-Disease O I-Disease
( B-Disease O B-Disease O
hemiplegia I-Disease U-Disease I-Disease B-Disease
<OOV> L-Disease O I-Disease O
<OOV> O O O O
) O O O O
observed O O O O
in O O O O
this O O O O
patient O O O O
supports O O O O
the O O O O
hypothesis O O O O
of O O O O
the O O O O
existence O O O O
of O O O O
an O O O O
uncrossed O O O O
excitatory O O O O
and O O O O
a O O O O
crossed O O O O
inhibitory O O O O
<OOV> O O O O
sympathetic O O O O
pathway O O O O
. O O O O
erythema B-Disease B-Disease B-Disease B-Disease
multiforme I-Disease L-Disease I-Disease I-Disease
minor L-Disease O I-Disease O
following O O O O
vaccination O O O O
with O O O O
paediatric O O O O
vaccines O O O O
. O O O O
we O O O O
present O O O O
0 O O O O
cases O O O O
of O O O O
erythema B-Disease B-Disease B-Disease B-Disease
multiforme L-Disease L-Disease I-Disease I-Disease
following O O O O
a O O O O
combined O O O O
tetanus U-Disease U-Disease B-Disease B-Disease
and O O O O
diphtheria U-Disease B-Disease B-Disease B-Disease
revaccination O L-Disease O I-Disease
and O O O O
a O O O O
combined O O O O
diphtheria U-Disease U-Disease B-Disease B-Disease
, O O O O
tetanus U-Disease U-Disease B-Disease B-Disease
, O O O O
acellular O B-Disease O B-Disease
pertussis U-Disease L-Disease B-Disease I-Disease
inactivated O O O O
polio U-Disease O B-Disease O
and O O O O
<OOV> B-Disease O B-Disease O
influenzae L-Disease B-Disease I-Disease B-Disease
type O I-Disease O I-Disease
b O L-Disease O I-Disease
vaccine O O O O
respectively O O O O
, O O O O
suggesting O O O O
vaccines O O O O
containing O O O O
diphtheria U-Disease O B-Disease O
and O O O O
tetanus U-Disease O B-Disease O
toxoids O O O O
as O O O O
a O O O O
potential O O O O
precipitating O O O O
factor O O O O
to O O O O
erythema B-Disease B-Disease B-Disease B-Disease
multiforme L-Disease L-Disease I-Disease I-Disease
. O O O O
subperiosteal B-Disease B-Disease B-Disease B-Disease
osteoid I-Disease I-Disease I-Disease I-Disease
osteoma L-Disease I-Disease I-Disease I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
distal O I-Disease O I-Disease
phalanx O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
thumb O L-Disease O I-Disease
. O O O O
osteoid B-Disease B-Disease B-Disease B-Disease
osteomas L-Disease L-Disease I-Disease I-Disease
have O O O O
been O O O O
subgrouped O O O O
into O O O O
subperiosteal O B-Disease O B-Disease
, O I-Disease O I-Disease
cancellous O L-Disease O I-Disease
, O O O O
and O O O O
cortical O O O O
. O O O O
the O O O O
occurrence O O O O
of O O O O
subperiosteal U-Disease B-Disease B-Disease B-Disease
osteoid O I-Disease O I-Disease
osteoma O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
hand O L-Disease O I-Disease
is O O O O
rare O O O O
. O O O O
the O O O O
location O O O O
in O O O O
the O O O O
distal O B-Disease O B-Disease
phalanx O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
thumb O L-Disease O I-Disease
has O O O O
not O O O O
been O O O O
described O O O O
. O O O O
the O O O O
case O O O O
reported O O O O
illustrates O O O O
the O O O O
unusual O O O O
presentation O O O O
and O O O O
radiographic O O O O
features O O O O
of O O O O
subperiosteal B-Disease B-Disease B-Disease B-Disease
osteoid I-Disease I-Disease I-Disease I-Disease
osteoma L-Disease L-Disease I-Disease I-Disease
. O O O O
relief O O O O
of O O O O
factitious B-Disease B-Disease B-Disease B-Disease
coarctation L-Disease L-Disease I-Disease I-Disease
following O O O O
occlusion O B-Disease O B-Disease
of O I-Disease O I-Disease
large O I-Disease O I-Disease
patent B-Disease I-Disease B-Disease I-Disease
ductus I-Disease I-Disease I-Disease I-Disease
arteriosus L-Disease L-Disease I-Disease I-Disease
with O O O O
gianturco O B-Disease O B-Disease
- O I-Disease O I-Disease
<OOV> O I-Disease O I-Disease
vascular O I-Disease O I-Disease
occluder O L-Disease O I-Disease
. O O O O
we O O O O
report O O O O
an O O O O
infant O O O O
with O O O O
a O O O O
large O O O O
patent B-Disease B-Disease B-Disease B-Disease
ductus I-Disease I-Disease I-Disease I-Disease
arteriosus L-Disease L-Disease I-Disease I-Disease
( O O O O
pda U-Disease U-Disease B-Disease B-Disease
) O O O O
and O O O O
a O O O O
hypoplastic O B-Disease O B-Disease
aortic O I-Disease O I-Disease
isthmus O L-Disease O I-Disease
presenting O O O O
with O O O O
factitious B-Disease B-Disease B-Disease B-Disease
coarctation L-Disease L-Disease I-Disease I-Disease
due O O O O
to O O O O
high O O O O
ductal O B-Disease O B-Disease
flow O L-Disease O I-Disease
. O O O O
following O O O O
transcatheter O O O O
occlusion O O O O
of O O O O
the O O O O
pda U-Disease U-Disease B-Disease B-Disease
with O O O O
a O O O O
gianturco O B-Disease O B-Disease
- O I-Disease O I-Disease
<OOV> O I-Disease O I-Disease
vascular O I-Disease O I-Disease
occluder O L-Disease O I-Disease
, O O O O
the O O O O
aortic O O O O
gradient O O O O
resolved O O O O
, O O O O
thereby O O O O
eliminating O O O O
the O O O O
need O O O O
for O O O O
surgery O O O O
on O O O O
the O O O O
isthmus O O O O
. O O O O
coexisting O B-Disease O B-Disease
central O I-Disease O I-Disease
diabetes B-Disease I-Disease B-Disease I-Disease
insipidus L-Disease L-Disease I-Disease I-Disease
and O O O O
psychogenic B-Disease B-Disease B-Disease B-Disease
polydipsia L-Disease L-Disease I-Disease I-Disease
. O O O O
a O O O O
chronic O O O O
schizophrenic O U-Disease O B-Disease
patient O O O O
is O O O O
described O O O O
in O O O O
whom O O O O
central O O O O
diabetes B-Disease B-Disease B-Disease B-Disease
insipidus L-Disease L-Disease I-Disease I-Disease
and O O O O
psychogenic B-Disease B-Disease B-Disease B-Disease
polydipsia L-Disease L-Disease I-Disease I-Disease
coexisted O O O O
. O O O O
a O O O O
possible O O O O
relationship O O O O
between O O O O
psychogenic B-Disease B-Disease B-Disease B-Disease
polydipsia L-Disease L-Disease I-Disease I-Disease
and O O O O
failure O B-Disease O B-Disease
of O I-Disease O I-Disease
vasopressin O I-Disease O I-Disease
release O L-Disease O I-Disease
is O O O O
hypothesized O O O O
. O O O O
lung B-Disease B-Disease B-Disease B-Disease
neoplasm L-Disease L-Disease I-Disease I-Disease
mimicking O O O O
an O O O O
acute O B-Disease O B-Disease
lateral O I-Disease O I-Disease
myocardial B-Disease I-Disease B-Disease I-Disease
infarction L-Disease L-Disease I-Disease I-Disease
. O O O O
involvement O O O O
of O O O O
the O O O O
heart O B-Disease O B-Disease
and O I-Disease O I-Disease
pericardium O L-Disease O I-Disease
by O O O O
cancer U-Disease U-Disease B-Disease B-Disease
is O O O O
not O O O O
uncommon O O O O
, O O O O
with O O O O
metastases O U-Disease O B-Disease
being O O O O
more O O O O
frequent O O O O
than O O O O
primary O O O O
cardiac B-Disease B-Disease B-Disease B-Disease
neoplasms L-Disease L-Disease I-Disease I-Disease
. O O O O
we O O O O
present O O O O
a O O O O
case O O O O
of O O O O
a O O O O
metastatic B-Disease B-Disease B-Disease B-Disease
lung I-Disease I-Disease I-Disease I-Disease
cancer L-Disease L-Disease I-Disease I-Disease
for O O O O
which O O O O
the O O O O
primary O O O O
manifestation O O O O
was O O O O
chest O O O O
pain O O O O
mimicking O O O O
an O O O O
acute O O O O
myocardial B-Disease B-Disease B-Disease B-Disease
infarction L-Disease L-Disease I-Disease I-Disease
. O O O O
analysis O O O O
of O O O O
rotaviral B-Disease B-Disease B-Disease B-Disease
gastroenteritis L-Disease L-Disease I-Disease I-Disease
in O O O O
tbilisi O O O O
. O O O O
<OOV> O O O O
of O O O O
000 O O O O
rotaviral O O O O
isolates O O O O
collected O O O O
in O O O O
tbilisi O O O O
for O O O O
00 O O O O
months O O O O
revealed O O O O
seven O O O O
patterns O O O O
from O O O O
which O O O O
0 O O O O
were O O O O
<OOV> O O O O
long O O O O
<OOV> O O O O
and O O O O
0 O O O O
<OOV> O O O O
short O O O O
<OOV> O O O O
. O O O O
the O O O O
<OOV> O O O O
long O O O O
<OOV> O O O O
<OOV> O O O O
represented O O O O
00 O O O O
. O O O O
0 O O O O
% O O O O
of O O O O
total O O O O
number O O O O
of O O O O
the O O O O
isolates O O O O
analysed O O O O
. O O O O
one O O O O
of O O O O
the O O O O
<OOV> O O O O
long O O O O
<OOV> O O O O
<OOV> O O O O
dominated O O O O
for O O O O
the O O O O
whole O O O O
investigation O O O O
period O O O O
. O O O O
differences O O O O
in O O O O
the O O O O
seasonal O O O O
distribution O O O O
of O O O O
the O O O O
isolates O O O O
with O O O O
various O O O O
<OOV> O O O O
were O O O O
demonstrated O O O O
and O O O O
appearance O O O O
of O O O O
rotaviral O O O O
isolates O O O O
was O O O O
registered O O O O
with O O O O
a O O O O
<OOV> O O O O
short O O O O
<OOV> O O O O
<OOV> O O O O
which O O O O
had O O O O
never O O O O
been O O O O
detected O O O O
before O O O O
. O O O O
radioimmunoassay O O O O
of O O O O
human O O O O
hageman O O O O
factor O O O O
( O O O O
factor O O O O
xii O O O O
) O O O O
. O O O O
a O O O O
<OOV> O O O O
, O O O O
sensitive O O O O
, O O O O
and O O O O
reproducible O O O O
radioimmunoassay O O O O
for O O O O
human O O O O
hageman O O O O
factor O O O O
( O O O O
hf O O O O
, O O O O
factory O O O O
xii O O O O
) O O O O
has O O O O
been O O O O
developed O O O O
with O O O O
purified O O O O
human O O O O
hf O O O O
and O O O O
monospecific O O O O
rabbit O O O O
antibody O O O O
. O O O O
precise O O O O
measurements O O O O
of O O O O
hf O U-Disease O B-Disease
antigen O O O O
were O O O O
possible O O O O
for O O O O
concentrations O O O O
as O O O O
low O O O O
as O O O O
0 O O O O
. O O O O
0 O O O O
% O O O O
of O O O O
that O O O O
in O O O O
normal O O O O
pooled O O O O
plasma O O O O
. O O O O
a O O O O
good O O O O
correlation O O O O
( O O O O
correlation O O O O
co O O O O
- O O O O
efficient O O O O
= O O O O
0 O O O O
. O O O O
00 O O O O
) O O O O
existed O O O O
between O O O O
the O O O O
titers O O O O
of O O O O
hf O U-Disease O B-Disease
measured O O O O
by O O O O
clot O O O O
- O O O O
promoting O O O O
assays O O O O
and O O O O
radioimmunoassays O O O O
among O O O O
00 O O O O
normal O O O O
adults O O O O
. O O O O
confirming O O O O
earlier O O O O
studies O O O O
, O O O O
hf O U-Disease O B-Disease
antigen O O O O
was O O O O
absent O O O O
in O O O O
hageman O O O O
trait O O O O
plasma O O O O
, O O O O
but O O O O
other O O O O
congenital O B-Disease O B-Disease
deficient O L-Disease O I-Disease
plasmas O O O O
, O O O O
including O O O O
those O O O O
of O O O O
individuals O O O O
with O O O O
fletcher O U-Disease O B-Disease
trait O O O O
and O O O O
fitzgerald O O O O
trait O O O O
, O O O O
contained O O O O
normal O O O O
amounts O O O O
of O O O O
hf O U-Disease O B-Disease
antigen O O O O
. O O O O
hf O O O O
antigen O O O O
was O O O O
reduced O O O O
in O O O O
the O O O O
plasmas O O O O
of O O O O
patients O O O O
with O O O O
disseminated B-Disease B-Disease B-Disease B-Disease
intravascular I-Disease I-Disease I-Disease I-Disease
coagulation L-Disease I-Disease I-Disease I-Disease
or O I-Disease O I-Disease
advanced O I-Disease O I-Disease
liver O I-Disease O I-Disease
cirrhosis U-Disease L-Disease B-Disease I-Disease
, O O O O
but O O O O
it O O O O
was O O O O
normal O O O O
in O O O O
those O O O O
of O O O O
patients O O O O
with O O O O
chronic B-Disease B-Disease B-Disease B-Disease
renal I-Disease I-Disease I-Disease I-Disease
failure L-Disease L-Disease I-Disease I-Disease
or O O O O
patients O O O O
under O O O O
treatment O O O O
with O O O O
warfarin O U-Disease O B-Disease
. O O O O
hf O U-Disease O B-Disease
antigen O O O O
was O O O O
detected O O O O
by O O O O
this O O O O
assay O O O O
in O O O O
plasmas O O O O
of O O O O
primates O O O O
, O O O O
but O O O O
not O O O O
detectable O O O O
in O O O O
plasmas O O O O
of O O O O
00 O O O O
nonprimate O O O O
mammalian O O O O
and O O O O
one O O O O
avian O O O O
species O O O O
. O O O O
progressive O B-Disease O B-Disease
facial O I-Disease O I-Disease
hemiatrophy O L-Disease O I-Disease
after O O O O
epileptic B-Disease B-Disease B-Disease B-Disease
seizures L-Disease L-Disease I-Disease I-Disease
. O O O O
intractable O O O O
complex O O O O
partial O O O O
seizures U-Disease U-Disease B-Disease B-Disease
developed O O O O
in O O O O
a O O O O
0 O O O O
- O O O O
year O O O O
- O O O O
old O O O O
female O O O O
with O O O O
normal O O O O
intracranial O O O O
findings O O O O
on O O O O
computed O O O O
tomography O O O O
. O O O O
frontal O O O O
paramedian O O O O
band O O O O
- O O O O
like O O O O
depression O B-Disease O B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
skin O L-Disease O I-Disease
gradually O O O O
developed O O O O
thereafter O O O O
, O O O O
and O O O O
progressive O B-Disease O B-Disease
facial B-Disease I-Disease B-Disease I-Disease
hemiatrophy L-Disease L-Disease I-Disease I-Disease
( O O O O
parry B-Disease B-Disease B-Disease B-Disease
- I-Disease I-Disease I-Disease I-Disease
romberg I-Disease I-Disease I-Disease I-Disease
syndrome L-Disease L-Disease I-Disease I-Disease
) O O O O
was O O O O
diagnosed O O O O
. O O O O
computed O O O O
tomography O O O O
scanning O O O O
at O O O O
0 O O O O
years O O O O
of O O O O
age O O O O
revealed O O O O
multiple O B-Disease O B-Disease
parenchymal O I-Disease O I-Disease
calcifications O L-Disease O I-Disease
and O O O O
low O O O O
- O O O O
density O O O O
areas O O O O
in O O O O
the O O O O
white O B-Disease O B-Disease
matter O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
frontoparietal O I-Disease O I-Disease
lobes O L-Disease O I-Disease
. O O O O
epileptic B-Disease B-Disease B-Disease B-Disease
seizures L-Disease L-Disease I-Disease I-Disease
, O O O O
one O O O O
of O O O O
the O O O O
major O O O O
neurologic O O O O
complications O O O O
of O O O O
progressive O B-Disease O B-Disease
facial B-Disease I-Disease B-Disease I-Disease
hemiatrophy L-Disease L-Disease I-Disease I-Disease
, O O O O
could O O O O
precede O O O O
the O O O O
succeeding O O O O
neurocutaneous O O O O
changes O O O O
. O O O O
blood O O O O
lead O O O O
levels O O O O
in O O O O
a O O O O
remote O O O O
, O O O O
unpolluted O O O O
rural O O O O
area O O O O
in O O O O
south O O O O
africa O O O O
. O O O O
the O O O O
whole O O O O
- O O O O
blood O O O O
lead O O O O
levels O O O O
of O O O O
00 O O O O
- O O O O
00 O O O O
- O O O O
year O O O O
- O O O O
olds O O O O
in O O O O
a O O O O
remote O O O O
, O O O O
unpolluted O O O O
rural O O O O
area O O O O
( O O O O
<OOV> O O O O
, O O O O
north O O O O
- O O O O
western O O O O
cape O O O O
province O O O O
) O O O O
were O O O O
determined O O O O
. O O O O
graphite O O O O
- O O O O
furnace O O O O
atomic O O O O
absorption O O O O
spectrometry O O O O
was O O O O
used O O O O
to O O O O
analyse O O O O
lead O O O O
levels O O O O
. O O O O
the O O O O
mean O O O O
whole O O O O
- O O O O
blood O O O O
lead O O O O
level O O O O
was O O O O
found O O O O
to O O O O
be O O O O
0 O O O O
, O O O O
0 O O O O
micrograms O O O O
/ O O O O
dl O O O O
. O O O O
this O O O O
value O O O O
should O O O O
also O O O O
be O O O O
considered O O O O
to O O O O
be O O O O
representative O O O O
of O O O O
the O O O O
natural O O O O
' O O O O
background O O O O
' O O O O
whole O O O O
- O O O O
blood O O O O
lead O O O O
level O O O O
of O O O O
south O O O O
africans O O O O
. O O O O
the O O O O
a O O O O
- O O O O
o O O O O
femoral O O O O
distractor O O O O
for O O O O
ankle O B-Disease O B-Disease
arthroscopy O L-Disease O I-Disease
. O O O O
arthroscopy O O O O
of O O O O
the O O O O
ankle O O O O
is O O O O
a O O O O
well O O O O
established O O O O
technique O O O O
for O O O O
the O O O O
evaluation O O O O
of O O O O
ankle O B-Disease O B-Disease
pain O L-Disease O I-Disease
or O O O O
dysfunction O U-Disease O B-Disease
. O O O O
using O O O O
the O O O O
a O O O O
- O O O O
o O O O O
femoral O O O O
distractor O O O O
with O O O O
pins O O O O
in O O O O
the O O O O
distal O O O O
tibia O O O O
and O O O O
calcaneum O O O O
, O O O O
respectively O O O O
, O O O O
we O O O O
were O O O O
able O O O O
to O O O O
provide O O O O
distraction O O O O
for O O O O
easy O O O O
visualization O O O O
and O O O O
operative O O O O
manipulation O O O O
within O O O O
the O O O O
ankle O B-Disease O B-Disease
joint O L-Disease O I-Disease
comparable O O O O
with O O O O
that O O O O
obtained O O O O
with O O O O
commercially O O O O
available O O O O
ankle O O O O
distractors O O O O
. O O O O
broad O O O O
band O O O O
spectral O O O O
eeg O O O O
parameters O O O O
correlated O O O O
with O O O O
different O O O O
iq O O O O
measurements O O O O
. O O O O
the O O O O
relationship O O O O
of O O O O
iq O O O O
( O O O O
measured O O O O
by O O O O
wais O O O O
and O O O O
all O O O O
its O O O O
subscales O O O O
) O O O O
and O O O O
eeg O O O O
broad O O O O
band O O O O
spectral O O O O
parameters O O O O
were O O O O
studied O O O O
in O O O O
00 O O O O
right O O O O
- O O O O
handed O O O O
, O O O O
male O O O O
volunteers O O O O
ranging O O O O
in O O O O
age O O O O
from O O O O
00 O O O O
to O O O O
00 O O O O
years O O O O
old O O O O
. O O O O
eegs O O O O
were O O O O
recorded O O O O
in O O O O
00 O O O O
derivations O O O O
during O O O O
rest O O O O
with O O O O
eyes O O O O
opened O O O O
. O O O O
the O O O O
results O O O O
obtained O O O O
reveal O O O O
positive O O O O
and O O O O
negative O O O O
correlations O O O O
with O O O O
abundant O O O O
frontal O O O O
participation O O O O
in O O O O
all O O O O
bands O O O O
. O O O O
mean O O O O
frequency O O O O
data O O O O
show O O O O
a O O O O
frequency O O O O
shift O O O O
in O O O O
a O O O O
very O O O O
narrow O O O O
range O O O O
suggesting O O O O
that O O O O
more O O O O
relations O O O O
in O O O O
narrow O O O O
band O O O O
could O O O O
be O O O O
achieved O O O O
. O O O O
these O O O O
results O O O O
highlight O O O O
the O O O O
need O O O O
of O O O O
psychological O O O O
tests O O O O
that O O O O
measure O O O O
more O O O O
homogeneous O O O O
abilities O O O O
and O O O O
finer O O O O
measurement O O O O
technique O O O O
to O O O O
reveal O O O O
clearly O O O O
explainable O O O O
correlations O O O O
and O O O O
demonstrate O O O O
that O O O O
eeg O O O O
recordings O O O O
do O O O O
reflect O O O O
intellectual O O O O
abilities O O O O
. O O O O
a O O O O
case O O O O
of O O O O
area O O O O
- O O O O
specific O O O O
stimulus O O O O
- O O O O
sensitive O O O O
postanoxic B-Disease O B-Disease O
myoclonus L-Disease U-Disease I-Disease B-Disease
. O O O O
the O O O O
authors O O O O
report O O O O
a O O O O
case O O O O
of O O O O
area O O O O
- O O O O
specific O O O O
stimulus O O O O
- O O O O
sensitive O O O O
postanoxic B-Disease O B-Disease O
myoclonus L-Disease U-Disease I-Disease B-Disease
and O O O O
discuss O O O O
possible O O O O
pathophysiology O O O O
. O O O O
a O O O O
00 O O O O
- O O O O
year O O O O
- O O O O
old O O O O
man O O O O
sustained O O O O
cardiorespiratory B-Disease B-Disease B-Disease B-Disease
arrest L-Disease L-Disease I-Disease I-Disease
that O O O O
lasted O O O O
00 O O O O
minutes O O O O
and O O O O
remained O O O O
unresponsive O O O O
. O O O O
on O O O O
the O O O O
first O O O O
eeg O O O O
obtained O O O O
0 O O O O
hours O O O O
after O O O O
the O O O O
arrest O O O O
there O O O O
was O O O O
no O O O O
cerebral O O O O
electrical O O O O
activity O O O O
before O O O O
stimulation O O O O
of O O O O
the O O O O
trigeminal O O O O
- O O O O
innervated O O O O
areas O O O O
. O O O O
periorbital O O O O
stimulation O O O O
was O O O O
associated O O O O
with O O O O
bursts O O O O
of O O O O
spike O O O O
- O O O O
wave O O O O
activity O O O O
and O O O O
generalized O B-Disease O B-Disease
myoclonic O I-Disease O I-Disease
jerks O L-Disease O I-Disease
, O O O O
whereas O O O O
other O O O O
types O O O O
of O O O O
stimulation O O O O
did O O O O
not O O O O
elicit O O O O
any O O O O
response O O O O
. O O O O
a O O O O
second O O O O
eeg O O O O
obtained O O O O
00 O O O O
hours O O O O
later O O O O
showed O O O O
a O O O O
nonreactive O O O O
alpha O O O O
coma O O O O
pattern O O O O
. O O O O
the O O O O
patient O O O O
died O O O O
0 O O O O
days O O O O
after O O O O
the O O O O
arrest O O O O
. O O O O
area O O O O
- O O O O
specific O O O O
stimulus O O O O
- O O O O
sensitive O O O O
postanoxic B-Disease O B-Disease O
myoclonus L-Disease U-Disease I-Disease B-Disease
is O O O O
very O O O O
rare O O O O
. O O O O
the O O O O
regularity O O O O
of O O O O
generalized O O O O
bursts O O O O
of O O O O
spike O O O O
- O O O O
wave O O O O
activity O O O O
( O O O O
cortical O O O O
response O O O O
) O O O O
in O O O O
response O O O O
to O O O O
stimulation O O O O
of O O O O
trigeminal O O O O
- O O O O
innervated O O O O
areas O O O O
suggests O O O O
that O O O O
the O O O O
resting O O O O
eeg O O O O
electrocerebral O O O O
silence O O O O
may O O O O
have O O O O
been O O O O
a O O O O
result O O O O
of O O O O
cortical O O O O
suppression O O O O
with O O O O
disinhibition O O O O
of O O O O
stimulus O B-Disease O B-Disease
- O I-Disease O I-Disease
sensitive O I-Disease O I-Disease
brainstem O I-Disease O I-Disease
- O I-Disease O I-Disease
generated O I-Disease O I-Disease
myoclonus U-Disease L-Disease B-Disease I-Disease
. O O O O
on O O O O
the O O O O
clinical O O O O
entity O O O O
in O O O O
audiology O U-Disease O B-Disease
: O O O O
( O O O O
central O O O O
) O O O O
auditory O O O O
processing O O O O
and O O O O
speech O O O O
recognition O O O O
in O O O O
noise B-Disease B-Disease B-Disease B-Disease
disorders L-Disease L-Disease I-Disease I-Disease
. O O O O
background O O O O
: O O O O
the O O O O
area O O O O
of O O O O
( B-Disease O B-Disease O
central I-Disease O I-Disease O
) I-Disease O I-Disease O
auditory I-Disease B-Disease I-Disease B-Disease
processing I-Disease I-Disease I-Disease I-Disease
disorder L-Disease L-Disease I-Disease I-Disease
[ O O O O
( B-Disease O B-Disease O
c I-Disease O I-Disease O
) I-Disease O I-Disease O
apd L-Disease U-Disease I-Disease B-Disease
] O O O O
is O O O O
highly O O O O
controversial O O O O
. O O O O
this O O O O
controversy O O O O
is O O O O
fueled O O O O
in O O O O
part O O O O
by O O O O
multiple O O O O
ambiguous O O O O
descriptions O O O O
of O O O O
this O O O O
condition O O O O
. O O O O
the O O O O
american O O O O
speech O B-Disease O B-Disease
- O I-Disease O I-Disease
language O I-Disease O I-Disease
and O I-Disease O I-Disease
hearing O L-Disease O I-Disease
association O O O O
and O O O O
the O O O O
american O O O O
academy O O O O
of O O O O
audiology O O O O
state O O O O
that O O O O
( B-Disease O B-Disease O
c I-Disease O I-Disease O
) I-Disease O I-Disease O
apd L-Disease U-Disease I-Disease B-Disease
is O O O O
a O O O O
clinical O O O O
entity O O O O
, O O O O
but O O O O
other O O O O
sources O O O O
say O O O O
that O O O O
this O O O O
is O O O O
questionable O O O O
. O O O O
the O O O O
clinical O O O O
entity O O O O
is O O O O
a O O O O
concept O O O O
used O O O O
to O O O O
define O O O O
the O O O O
nature O O O O
of O O O O
a O O O O
disorder O O O O
in O O O O
order O O O O
to O O O O
facilitate O O O O
diagnosis O O O O
and O O O O
intervention O O O O
. O O O O
nosography O O O O
is O O O O
the O O O O
study O O O O
of O O O O
the O O O O
systematic O O O O
description O O O O
of O O O O
diseases O O O O
and O O O O
disorders O O O O
. O O O O
the O O O O
work O O O O
in O O O O
the O O O O
field O O O O
of O O O O
nosography O O O O
by O O O O
physicians O O O O
thomas O O O O
sydenham O B-Disease O B-Disease
and O I-Disease O I-Disease
otto O I-Disease O I-Disease
<OOV> O L-Disease O I-Disease
is O O O O
reviewed O O O O
. O O O O
purpose O O O O
: O O O O
the O O O O
sydenham O B-Disease O B-Disease
- O I-Disease O I-Disease
<OOV> O L-Disease O I-Disease
criteria O O O O
for O O O O
the O O O O
clinical O O O O
entity O O O O
are O O O O
presented O O O O
as O O O O
a O O O O
framework O O O O
for O O O O
the O O O O
conceptualization O O O O
of O O O O
disorders O O O O
in O O O O
the O O O O
field O O O O
of O O O O
audiology O O O O
. O O O O
this O O O O
paper O O O O
discusses O O O O
central B-Disease O B-Disease O
auditory I-Disease O I-Disease O
processing I-Disease O I-Disease O
and I-Disease O I-Disease O
speech I-Disease B-Disease I-Disease B-Disease
recognition I-Disease I-Disease I-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
in I-Disease I-Disease I-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
noise I-Disease I-Disease I-Disease I-Disease
disorders L-Disease L-Disease I-Disease I-Disease
in O O O O
reference O O O O
to O O O O
these O O O O
criteria O O O O
. O O O O
haemostatic B-Disease B-Disease B-Disease B-Disease
abnormalities L-Disease L-Disease I-Disease I-Disease
in O O O O
hepatosplenic B-Disease B-Disease B-Disease B-Disease
schistosomiasis L-Disease L-Disease I-Disease I-Disease
mansoni O O O O
. O O O O
hepatosplenic B-Disease B-Disease B-Disease B-Disease
schistosomiasis L-Disease L-Disease I-Disease I-Disease
is O O O O
a O O O O
complex O O O O
immuno B-Disease B-Disease B-Disease B-Disease
- I-Disease I-Disease I-Disease I-Disease
regulatory I-Disease I-Disease I-Disease I-Disease
disease L-Disease L-Disease I-Disease I-Disease
and O O O O
is O O O O
major O O O O
health O O O O
problem O O O O
in O O O O
endemic O O O O
countries O O O O
. O O O O
acute O O O O
bleeding O U-Disease O B-Disease
is O O O O
one O O O O
of O O O O
its O O O O
most O O O O
serious O O O O
complications O O O O
and O O O O
often O O O O
life O B-Disease O B-Disease
- O I-Disease O I-Disease
threatening O L-Disease O I-Disease
. O O O O
clinical O O O O
studies O O O O
have O O O O
demonstrated O O O O
that O O O O
the O O O O
patients O O O O
with O O O O
hepatosplenic B-Disease B-Disease B-Disease B-Disease
schistosomiasis L-Disease L-Disease I-Disease I-Disease
are O O O O
prone O O O O
to O O O O
develop O O O O
complex O O O O
haemostatic B-Disease B-Disease B-Disease B-Disease
abnormalities L-Disease L-Disease I-Disease I-Disease
that O O O O
may O O O O
be O O O O
linked O O O O
to O O O O
the O O O O
potential O O O O
risk O O O O
of O O O O
bleeding O U-Disease O B-Disease
from O O O O
ruptured B-Disease O B-Disease O
esophageal I-Disease B-Disease I-Disease B-Disease
varices L-Disease L-Disease I-Disease I-Disease
in O O O O
these O O O O
patients O O O O
. O O O O
the O O O O
deficit O O O O
in O O O O
haemostatic O O O O
parameters O O O O
is O O O O
more O O O O
pronounced O O O O
with O O O O
the O O O O
advancement O O O O
of O O O O
the O O O O
disease O O O O
and O O O O
is O O O O
maximal O O O O
in O O O O
the O O O O
patients O O O O
with O O O O
experience O O O O
of O O O O
<OOV> U-Disease O B-Disease O
. O O O O
evidences O O O O
of O O O O
enhanced O O O O
generation O O O O
of O O O O
thrombin O O O O
and O O O O
plasmin O O O O
indicate O O O O
the O O O O
presence O O O O
of O O O O
low O O O O
- O O O O
grade O O O O
dic U-Disease U-Disease B-Disease B-Disease
in O O O O
advanced O B-Disease O B-Disease
hepatosplenic B-Disease I-Disease B-Disease I-Disease
schistosomiasis L-Disease L-Disease I-Disease I-Disease
, O O O O
which O O O O
is O O O O
considered O O O O
as O O O O
a O O O O
principal O O O O
cause O O O O
of O O O O
haemostatic B-Disease B-Disease B-Disease B-Disease
abnormalities L-Disease L-Disease I-Disease I-Disease
in O O O O
this O O O O
endemic O O O O
disease O O O O
. O O O O
demonstration O O O O
of O O O O
procoagulant O O O O
expression O O O O
in O O O O
peripheral O O O O
blood O O O O
monocytes O O O O
of O O O O
the O O O O
patients O O O O
and O O O O
in O O O O
the O O O O
livers O O O O
, O O O O
spleens O O O O
and O O O O
intestines O O O O
of O O O O
s O O O O
. O O O O
mansoni O O O O
- O O O O
infected O O O O
mice O O O O
suggest O O O O
their O O O O
possible O O O O
implication O O O O
in O O O O
the O O O O
causation O O O O
of O O O O
dic U-Disease U-Disease B-Disease B-Disease
in O O O O
s B-Disease O B-Disease O
. I-Disease O I-Disease O
mansoni I-Disease O I-Disease O
infections L-Disease O I-Disease O
. O O O O
moreover O O O O
, O O O O
because O O O O
in O O O O
vitro O O O O
analysis O O O O
indicates O O O O
a O O O O
participation O O O O
of O O O O
immune O O O O
mechanisms O O O O
in O O O O
the O O O O
localized O O O O
procoagulant O O O O
expression O O O O
, O O O O
it O O O O
seems O O O O
likely O O O O
that O O O O
the O O O O
immune O O O O
responses O O O O
to O O O O
schistosomes O O O O
play O O O O
a O O O O
major O O O O
role O O O O
in O O O O
the O O O O
pathogenic O O O O
mechanisms O O O O
of O O O O
haemostatic B-Disease B-Disease B-Disease B-Disease
abnormalities L-Disease L-Disease I-Disease I-Disease
in O O O O
hepatosplenic B-Disease B-Disease B-Disease B-Disease
schistosomiasis L-Disease L-Disease I-Disease I-Disease
. O O O O
squamous O B-Disease O B-Disease
- O I-Disease O I-Disease
cell O I-Disease O I-Disease
carcinoma O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
pleura O L-Disease O I-Disease
. O O O O
there O O O O
are O O O O
few O O O O
reports O O O O
of O O O O
primary O O O O
malignant B-Disease B-Disease B-Disease B-Disease
tumours I-Disease L-Disease I-Disease I-Disease
of I-Disease O I-Disease O
the I-Disease O I-Disease O
pleura L-Disease B-Disease I-Disease B-Disease
other O I-Disease O I-Disease
than O I-Disease O I-Disease
mesothelioma U-Disease L-Disease B-Disease I-Disease
. O O O O
reports O O O O
of O O O O
squamous B-Disease B-Disease B-Disease B-Disease
- I-Disease I-Disease I-Disease I-Disease
cell I-Disease I-Disease I-Disease I-Disease
carcinoma L-Disease I-Disease I-Disease I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
pleura O L-Disease O I-Disease
are O O O O
especially O O O O
rare O O O O
. O O O O
epidermoid B-Disease B-Disease B-Disease B-Disease
carcinoma L-Disease I-Disease I-Disease I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
pleura O L-Disease O I-Disease
may O O O O
occur O O O O
in O O O O
connection O O O O
with O O O O
persistent O O O O
empyema O U-Disease O B-Disease
drained O O O O
by O O O O
a O O O O
<OOV> B-Disease B-Disease B-Disease B-Disease
fistula L-Disease L-Disease I-Disease I-Disease
or O O O O
long O B-Disease O B-Disease
- O I-Disease O I-Disease
standing O I-Disease O I-Disease
extrapleural B-Disease I-Disease B-Disease I-Disease
pneumothorax L-Disease L-Disease I-Disease I-Disease
without O O O O
fistula O U-Disease O B-Disease
. O O O O
far O O O O
- O O O O
field O O O O
somatosensory O O O O
evoked O O O O
potentials O O O O
after O O O O
stimulation O B-Disease O B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
tibial O I-Disease O I-Disease
nerve O L-Disease O I-Disease
. O O O O
in O O O O
00 O O O O
normal O O O O
subjects O O O O
, O O O O
far O O O O
- O O O O
field O O O O
somatosensory O O O O
potentials O O O O
were O O O O
recorded O O O O
from O O O O
the O O O O
scalp O O O O
after O O O O
stimulation O O O O
of O O O O
the O O O O
tibial O O O O
nerve O O O O
at O O O O
the O O O O
ankle O O O O
( O O O O
tibial O O O O
sep O O O O
) O O O O
. O O O O
with O O O O
the O O O O
use O O O O
of O O O O
a O O O O
knee O O O O
reference O O O O
contralateral O O O O
to O O O O
the O O O O
side O O O O
of O O O O
stimulation O O O O
, O O O O
the O O O O
tibial O O O O
sep O O O O
consisted O O O O
of O O O O
three O O O O
major O O O O
positive O O O O
peaks O O O O
, O O O O
p00 O O O O
, O O O O
p00 O O O O
, O O O O
and O O O O
p00 O O O O
, O O O O
and O O O O
three O O O O
additional O O O O
but O O O O
inconsistent O O O O
components O O O O
, O O O O
p00 O O O O
, O O O O
p00 O O O O
, O O O O
and O O O O
p00 O O O O
. O O O O
presumable O O O O
generator O O O O
sources O O O O
of O O O O
the O O O O
tibial O B-Disease O B-Disease
sep O L-Disease O I-Disease
are O O O O
the O O O O
popliteal O O O O
fossa O O O O
for O O O O
p00 O O O O
, O O O O
entry O O O O
to O O O O
the O O O O
sacral O B-Disease O B-Disease
plexus O I-Disease O I-Disease
for O I-Disease O I-Disease
p00 O I-Disease O I-Disease
, O I-Disease O I-Disease
the O I-Disease O I-Disease
cauda O I-Disease O I-Disease
equina O I-Disease O I-Disease
for O I-Disease O I-Disease
p00 O L-Disease O I-Disease
, O O O O
entry O O O O
to O O O O
the O O O O
conus O O O O
medullaris O O O O
for O O O O
p00 O O O O
, O O O O
the O O O O
rostral O O O O
spinal O O O O
cord O O O O
for O O O O
p00 O O O O
, O O O O
and O O O O
the O O O O
brainstem O O O O
for O O O O
p00 O O O O
. O O O O
lymphogranuloma B-Disease O B-Disease O
venereum L-Disease B-Disease I-Disease B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
tonsil O L-Disease O I-Disease
. O O O O
a O O O O
case O O O O
of O O O O
lymphogranuloma B-Disease B-Disease B-Disease B-Disease
venereum L-Disease I-Disease I-Disease I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
tonsillar O I-Disease O I-Disease
lymph O I-Disease O I-Disease
tissue O L-Disease O I-Disease
is O O O O
presented O O O O
. O O O O
the O O O O
similarities O O O O
of O O O O
tonsils O B-Disease O B-Disease
to O I-Disease O I-Disease
cervical O I-Disease O I-Disease
lymph O I-Disease O I-Disease
nodes O L-Disease O I-Disease
are O O O O
discussed O O O O
and O O O O
the O O O O
importance O O O O
of O O O O
histological O O O O
examination O O O O
of O O O O
abnormal O O O O
tonsil O O O O
tissue O O O O
is O O O O
reiterated O O O O
. O O O O
elevated O O O O
<OOV> O O O O
prostate O O O O
- O O O O
specific O O O O
membrane O O O O
antigen O O O O
activity O O O O
in O O O O
metastatic O B-Disease O B-Disease
non B-Disease I-Disease B-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
small I-Disease I-Disease I-Disease I-Disease
cell I-Disease I-Disease I-Disease I-Disease
lung I-Disease I-Disease I-Disease I-Disease
cancer L-Disease L-Disease I-Disease I-Disease
. O O O O
a O O O O
00 O O O O
- O O O O
year O O O O
- O O O O
old O O O O
man O O O O
with O O O O
a O O O O
background O O O O
of O O O O
treated O B-Disease O B-Disease
stage O I-Disease O I-Disease
iiib O I-Disease O I-Disease
non B-Disease I-Disease B-Disease I-Disease
- I-Disease I-Disease I-Disease I-Disease
small I-Disease I-Disease I-Disease I-Disease
cell I-Disease I-Disease I-Disease I-Disease
lung I-Disease I-Disease I-Disease I-Disease
cancer L-Disease L-Disease I-Disease I-Disease
was O O O O
referred O O O O
for O O O O
ga O O O O
prostate O O O O
- O O O O
specific O O O O
membrane O O O O
antigen O O O O
( O O O O
psma O O O O
) O O O O
pet O O O O
/ O O O O
ct O O O O
for O O O O
staging O O O O
of O O O O
prostate B-Disease B-Disease B-Disease B-Disease
cancer L-Disease L-Disease I-Disease I-Disease
. O O O O
in O O O O
addition O O O O
to O O O O
the O O O O
psma O O O O
uptake O O O O
in O O O O
the O O O O
known O O O O
prostate B-Disease B-Disease B-Disease B-Disease
malignancy L-Disease L-Disease I-Disease I-Disease
, O O O O
the O O O O
study O O O O
also O O O O
demonstrated O O O O
increased O O O O
psma O O O O
uptake O O O O
in O O O O
an O O O O
enlarging O O O O
left B-Disease O B-Disease O
lower I-Disease O I-Disease O
lobe I-Disease O I-Disease O
lung I-Disease O I-Disease O
mass L-Disease O I-Disease O
with O O O O
diffusely O O O O
increased O O O O
psma O O O O
uptake O O O O
in O O O O
an O O O O
enlarged O B-Disease O B-Disease
thyroid O I-Disease O I-Disease
gland O L-Disease O I-Disease
and O O O O
bilateral O B-Disease O B-Disease
enlarged O I-Disease O I-Disease
supraclavicular O I-Disease O I-Disease
lymph O I-Disease O I-Disease
nodes O L-Disease O I-Disease
. O O O O
fine O B-Disease O B-Disease
- O I-Disease O I-Disease
needle O I-Disease O I-Disease
aspiration O I-Disease O I-Disease
biopsy O I-Disease O I-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
thyroid O I-Disease O I-Disease
gland O L-Disease O I-Disease
and O O O O
a O O O O
left O O O O
supraclavicular O B-Disease O B-Disease
lymph O L-Disease O I-Disease
node O O O O
demonstrated O O O O
metastatic O B-Disease O B-Disease
adenocarcinoma U-Disease L-Disease B-Disease I-Disease
from O O O O
a O O O O
primary O B-Disease O B-Disease
lung B-Disease I-Disease B-Disease I-Disease
cancer L-Disease L-Disease I-Disease I-Disease
. O O O O
alpha O O O O
- O O O O
interferon O O O O
in O O O O
hematological B-Disease B-Disease B-Disease B-Disease
malignancies L-Disease L-Disease I-Disease I-Disease
. O O O O
recent O O O O
studies O O O O
have O O O O
generated O O O O
data O O O O
demonstrating O O O O
significant O O O O
clinical O O O O
activity O O O O
of O O O O
alpha O B-Disease O B-Disease
- O I-Disease O I-Disease
interferon O L-Disease O I-Disease
therapy O O O O
in O O O O
each O O O O
of O O O O
six O O O O
hematological B-Disease B-Disease B-Disease B-Disease
malignancies L-Disease L-Disease I-Disease I-Disease
, O O O O
chronic B-Disease B-Disease B-Disease B-Disease
myeloid I-Disease I-Disease I-Disease I-Disease
leukaemia L-Disease L-Disease I-Disease I-Disease
, O O O O
essential B-Disease B-Disease B-Disease B-Disease
thrombocythemia L-Disease L-Disease I-Disease I-Disease
, O O O O
polycythemia U-Disease B-Disease B-Disease B-Disease
rubra O I-Disease O I-Disease
vera O L-Disease O I-Disease
, O O O O
non B-Disease B-Disease B-Disease B-Disease
- I-Disease I-Disease I-Disease I-Disease
hodgkin I-Disease I-Disease I-Disease I-Disease
' I-Disease I-Disease I-Disease I-Disease
s I-Disease I-Disease I-Disease I-Disease
lymphomas L-Disease L-Disease I-Disease I-Disease
, O O O O
multiple B-Disease B-Disease B-Disease B-Disease
myelomatosis L-Disease L-Disease I-Disease I-Disease
and O O O O
hairy B-Disease B-Disease B-Disease B-Disease
cell I-Disease I-Disease I-Disease I-Disease
leukaemia L-Disease L-Disease I-Disease I-Disease
. O O O O
coexisting O B-Disease O B-Disease
central O I-Disease O I-Disease
diabetes B-Disease I-Disease B-Disease I-Disease
insipidus L-Disease L-Disease I-Disease I-Disease
and O O O O
psychogenic B-Disease B-Disease B-Disease B-Disease
polydipsia L-Disease L-Disease I-Disease I-Disease
. O O O O
a O O O O
chronic O O O O
schizophrenic O U-Disease O B-Disease
patient O O O O
is O O O O
described O O O O
in O O O O
whom O O O O
central O O O O
diabetes B-Disease B-Disease B-Disease B-Disease
insipidus L-Disease L-Disease I-Disease I-Disease
and O O O O
psychogenic B-Disease B-Disease B-Disease B-Disease
polydipsia L-Disease L-Disease I-Disease I-Disease
coexisted O O O O
. O O O O
a O O O O
possible O O O O
relationship O O O O
between O O O O
psychogenic B-Disease B-Disease B-Disease B-Disease
polydipsia L-Disease L-Disease I-Disease I-Disease
and O O O O
failure O B-Disease O B-Disease
of O I-Disease O I-Disease
vasopressin O I-Disease O I-Disease
release O L-Disease O I-Disease
is O O O O
hypothesized O O O O
. O O O O
a O O O O
rapid O O O O
screen O O O O
of O O O O
the O O O O
severity O O O O
of O O O O
mild B-Disease O B-Disease O
traumatic I-Disease B-Disease I-Disease B-Disease
brain I-Disease I-Disease I-Disease I-Disease
injury L-Disease L-Disease I-Disease I-Disease
. O O O O
this O O O O
study O O O O
investigated O O O O
the O O O O
sensitivity O O O O
of O O O O
information O O O O
processing O O O O
, O O O O
recall O O O O
and O O O O
orientation O O O O
tasks O O O O
to O O O O
the O O O O
presence O O O O
of O O O O
mild B-Disease O B-Disease O
traumatic I-Disease B-Disease I-Disease B-Disease
brain I-Disease I-Disease I-Disease I-Disease
injury L-Disease L-Disease I-Disease I-Disease
( O O O O
mtbi U-Disease U-Disease B-Disease B-Disease
) O O O O
. O O O O
fifty O O O O
- O O O O
six O O O O
( O O O O
00 O O O O
male O O O O
, O O O O
00 O O O O
female O O O O
) O O O O
mtbi U-Disease U-Disease B-Disease B-Disease
patients O O O O
and O O O O
00 O O O O
( O O O O
00 O O O O
male O O O O
and O O O O
00 O O O O
female O O O O
) O O O O
controls O O O O
with O O O O
orthopaedic O B-Disease O B-Disease
injuries O L-Disease O I-Disease
were O O O O
tested O O O O
within O O O O
00 O O O O
hr O O O O
of O O O O
injury O O O O
in O O O O
the O O O O
department O O O O
of O O O O
emergency O O O O
medicine O O O O
. O O O O
mtbi U-Disease O B-Disease O
patients O O O O
answered O O O O
fewer O O O O
orientation O O O O
questions O O O O
and O O O O
recalled O O O O
fewer O O O O
words O O O O
in O O O O
delayed O O O O
recall O O O O
than O O O O
orthopaedic O O O O
patients O O O O
. O O O O
mtbi U-Disease O B-Disease O
patients O O O O
judged O O O O
fewer O O O O
sentences O O O O
in O O O O
0 O O O O
min O O O O
than O O O O
orthopaedic O O O O
controls O O O O
, O O O O
and O O O O
female O O O O
mtbi U-Disease O B-Disease O
patients O O O O
judged O O O O
fewer O O O O
sentences O O O O
than O O O O
male O B-Disease O B-Disease
mtbi U-Disease L-Disease B-Disease I-Disease
patients O O O O
. O O O O
male O O O O
mtbi U-Disease O B-Disease O
patients O O O O
correctly O O O O
recalled O O O O
fewer O O O O
words O O O O
during O O O O
immediate O O O O
memory O O O O
and O O O O
learning O O O O
than O O O O
female O O O O
mtbi U-Disease O B-Disease O
patients O O O O
and O O O O
orthopaedic O O O O
controls O O O O
. O O O O
those O O O O
mtbi U-Disease O B-Disease O
patients O O O O
with O O O O
a O O O O
history O O O O
of O O O O
previous O O O O
head B-Disease B-Disease B-Disease B-Disease
injuries L-Disease L-Disease I-Disease I-Disease
did O O O O
not O O O O
perform O O O O
more O O O O
poorly O O O O
than O O O O
those O O O O
mtbi U-Disease O B-Disease O
patients O O O O
without O O O O
previous O O O O
head B-Disease B-Disease B-Disease B-Disease
injuries L-Disease L-Disease I-Disease I-Disease
. O O O O
these O O O O
results O O O O
indicate O O O O
that O O O O
tests O O O O
of O O O O
speed O O O O
of O O O O
information O O O O
processing O O O O
, O O O O
word O O O O
learning O O O O
and O O O O
orientation O O O O
questions O O O O
are O O O O
sensitive O O O O
to O O O O
the O O O O
acute O O O O
effects O O O O
of O O O O
mtbi U-Disease U-Disease B-Disease B-Disease
. O O O O
an O O O O
a O O O O
gamma O O O O
globin O O O O
promoter O O O O
( O O O O
four O O O O
base O O O O
- O O O O
pair O O O O
deletion O O O O
) O O O O
mutant O O O O
shows O O O O
linked O O O O
polymorphic O O O O
changes O O O O
throughout O O O O
the O O O O
a O O O O
gamma O O O O
gene O O O O
. O O O O
the O O O O
a O O O O
gamma O O O O
fetal O O O O
globin O O O O
genes O O O O
from O O O O
a O O O O
large O O O O
australian O O O O
kindred O O O O
with O O O O
nondeletional O O O O
a O O O O
gamma O O O O
hereditary B-Disease O B-Disease O
persistence I-Disease O I-Disease O
of I-Disease O I-Disease O
fetal I-Disease O I-Disease O
hemoglobin L-Disease O I-Disease O
( O O O O
hpfh U-Disease O B-Disease O
) O O O O
were O O O O
cloned O O O O
and O O O O
sequenced O O O O
. O O O O
the O O O O
- O O O O
000 O O O O
t O O O O
- O O O O
- O O O O
- O O O O
- O O O O
c O O O O
mutation O O O O
( O O O O
british B-Disease O B-Disease O
type I-Disease O I-Disease O
hpfh L-Disease O I-Disease O
) O O O O
was O O O O
demonstrated O O O O
upstream O O O O
of O O O O
the O O O O
a O O O O
gamma O O O O
gene O O O O
on O O O O
one O O O O
allele O O O O
. O O O O
on O O O O
the O O O O
other O O O O
allele O O O O
, O O O O
a O O O O
0 O O O O
- O O O O
deletion O O O O
was O O O O
identified O O O O
- O O O O
000 O O O O
to O O O O
- O O O O
000 O O O O
bp O O O O
upstream O O O O
from O O O O
the O O O O
cap O O O O
site O O O O
. O O O O
the O O O O
0 O O O O
- O O O O
bp O O O O
deletion O O O O
allele O O O O
was O O O O
associated O O O O
with O O O O
a O O O O
number O O O O
of O O O O
variations O O O O
in O O O O
the O O O O
a O O O O
gamma O O O O
gene O O O O
sequence O O O O
: O O O O
ana O O O O
gamma O O O O
t O O O O
transition O O O O
, O O O O
in O O O O
the O O O O
second O O O O
exon O O O O
( O O O O
t O O O O
- O O O O
- O O O O
- O O O O
- O O O O
c O O O O
at O O O O
+ O O O O
000 O O O O
relative O O O O
to O O O O
the O O O O
cap O O O O
site O O O O
) O O O O
; O O O O
a O O O O
hindiii O O O O
polymorphism O O O O
in O O O O
the O O O O
second O O O O
intron O O O O
; O O O O
and O O O O
a O O O O
g O O O O
gamma O O O O
- O O O O
like O O O O
sequence O O O O
in O O O O
the O O O O
0 O O O O
' O O O O
untranslated O O O O
region O O O O
( O O O O
<OOV> O O O O
in O O O O
place O O O O
of O O O O
<OOV> O O O O
, O O O O
creating O O O O
a O O O O
saci O O O O
site O O O O
) O O O O
. O O O O
an O O O O
association O O O O
between O O O O
the O O O O
- O O O O
000 O O O O
to O O O O
- O O O O
000 O O O O
deletion O O O O
, O O O O
the O O O O
a O B-Disease O B-Disease
gamma O I-Disease O I-Disease
t O L-Disease O I-Disease
polymorphism O O O O
, O O O O
and O O O O
the O O O O
second O O O O
intron O O O O
hindiii O O O O
polymorphism O O O O
has O O O O
previously O O O O
been O O O O
reported O O O O
. O O O O
in O O O O
addition O O O O
, O O O O
linkage O O O O
of O O O O
the O O O O
hindiii O O O O
polymorphism O O O O
with O O O O
the O O O O
g O O O O
gamma O O O O
- O O O O
like O O O O
sequence O O O O
in O O O O
the O O O O
0 O O O O
' O O O O
untranslated O O O O
region O O O O
of O O O O
a O O O O
gamma O O O O
has O O O O
also O O O O
been O O O O
described O O O O
. O O O O
the O O O O
case O O O O
described O O O O
here O O O O
is O O O O
unique O O O O
, O O O O
with O O O O
all O O O O
four O O O O
changes O O O O
present O O O O
in O O O O
the O O O O
one O O O O
a O O O O
gamma O O O O
gene O O O O
. O O O O
it O O O O
is O O O O
also O O O O
noteworthy O O O O
because O O O O
there O O O O
is O O O O
simultaneous O O O O
occurrence O O O O
of O O O O
high O O O O
( O O O O
hpfh U-Disease O B-Disease O
) O O O O
and O O O O
low O O O O
( O O O O
- O O O O
000 O O O O
to O O O O
- O O O O
000 O O O O
deletion O O O O
) O O O O
expression O O O O
mutants O O O O
in O O O O
the O O O O
same O O O O
patient O O O O
. O O O O
despite O O O O
the O O O O
presence O O O O
of O O O O
the O O O O
0 O O O O
- O O O O
bp O O O O
deletion O O O O
, O O O O
the O O O O
resulting O O O O
hematological O O O O
phenotype O O O O
remained O O O O
that O O O O
of O O O O
hpfh U-Disease O B-Disease O
. O O O O
when O O O O
the O O O O
0 O O O O
- O O O O
bp O O O O
deletion O O O O
promoter O O O O
was O O O O
studied O O O O
in O O O O
a O O O O
<OOV> O O O O
- O O O O
cell O O O O
transient O O O O
expression O O O O
assay O O O O
, O O O O
there O O O O
was O O O O
found O O O O
to O O O O
be O O O O
no O O O O
statistically O O O O
significant O O O O
reduction O O O O
in O O O O
activity O O O O
compared O O O O
to O O O O
the O O O O
control O O O O
a O O O O
gamma O O O O
promoter O O O O
. O O O O
the O O O O
possible O O O O
reasons O O O O
for O O O O
the O O O O
observed O O O O
differences O O O O
between O O O O
the O O O O
in O O O O
vivo O O O O
and O O O O
in O O O O
vitro O O O O
activity O O O O
of O O O O
this O O O O
mutation O O O O
are O O O O
discussed O O O O
. O O O O
function O O O O
- O O O O
based O O O O
gene O O O O
identification O O O O
using O O O O
enzymatically O O O O
generated O O O O
normalized O O O O
shrna O O O O
library O O O O
and O O O O
massive O O O O
parallel O O O O
sequencing O O O O
. O O O O
as O O O O
a O O O O
general O O O O
strategy O O O O
for O O O O
function O O O O
- O O O O
based O O O O
gene O O O O
identification O O O O
, O O O O
an O O O O
shrna O O O O
library O O O O
containing O O O O
approximately O O O O
000 O O O O
shrnas O O O O
per O O O O
gene O O O O
was O O O O
enzymatically O O O O
generated O O O O
from O O O O
normalized O O O O
( O O O O
reduced O O O O
- O O O O
<OOV> O O O O
) O O O O
human O O O O
cdna O O O O
. O O O O
the O O O O
library O O O O
was O O O O
constructed O O O O
in O O O O
an O O O O
inducible O O O O
lentiviral O O O O
vector O O O O
, O O O O
enabling O O O O
propagation O O O O
of O O O O
growth O O O O
- O O O O
inhibiting O O O O
shrnas O O O O
and O O O O
controlled O O O O
activity O O O O
measurements O O O O
. O O O O
rnai O O O O
activities O O O O
were O O O O
measured O O O O
for O O O O
000 O O O O
shrna O O O O
clones O O O O
representing O O O O
000 O O O O
human O O O O
genes O O O O
and O O O O
for O O O O
000 O O O O
shrnas O O O O
derived O O O O
from O O O O
a O O O O
firefly O O O O
luciferase O O O O
gene O O O O
. O O O O
structure O O O O
- O O O O
activity O O O O
analysis O O O O
of O O O O
these O O O O
two O O O O
datasets O O O O
yielded O O O O
a O O O O
set O O O O
of O O O O
structural O O O O
criteria O O O O
for O O O O
shrna O O O O
efficacy O O O O
, O O O O
increasing O O O O
the O O O O
frequencies O O O O
of O O O O
active O O O O
shrnas O O O O
up O O O O
to O O O O
0 O O O O
- O O O O
fold O O O O
relative O O O O
to O O O O
random O O O O
sampling O O O O
. O O O O
the O O O O
same O O O O
library O O O O
was O O O O
used O O O O
to O O O O
select O O O O
shrnas O O O O
that O O O O
inhibit O O O O
breast B-Disease B-Disease B-Disease B-Disease
carcinoma L-Disease L-Disease I-Disease I-Disease
cell O O O O
growth O O O O
by O O O O
targeting O O O O
potential O O O O
oncogenes O O O O
. O O O O
genes O O O O
targeted O O O O
by O O O O
the O O O O
selected O O O O
shrnas O O O O
were O O O O
enriched O O O O
for O O O O
00 O O O O
pathways O O O O
, O O O O
0 O O O O
of O O O O
which O O O O
have O O O O
been O O O O
previously O O O O
associated O O O O
with O O O O
various O O O O
cancers U-Disease U-Disease B-Disease B-Disease
, O O O O
cell O O O O
cycle O O O O
progression O O O O
, O O O O
or O O O O
apoptosis O O O O
. O O O O
one O O O O
hundred O O O O
nineteen O O O O
genes O O O O
, O O O O
enriched O O O O
through O O O O
this O O O O
selection O O O O
and O O O O
represented O O O O
by O O O O
two O O O O
to O O O O
six O O O O
shrnas O O O O
each O O O O
, O O O O
were O O O O
identified O O O O
as O O O O
potential O O O O
cancer U-Disease U-Disease B-Disease B-Disease
drug O O O O
targets O O O O
. O O O O
short O O O O
interfering O O O O
rnas O O O O
against O O O O
00 O O O O
of O O O O
00 O O O O
tested O O O O
genes O O O O
in O O O O
this O O O O
group O O O O
inhibited O O O O
cell O O O O
growth O O O O
, O O O O
validating O O O O
the O O O O
efficiency O O O O
of O O O O
this O O O O
strategy O O O O
for O O O O
high O O O O
- O O O O
throughput O O O O
target O O O O
gene O O O O
identification O O O O
. O O O O
isolated O O O O
giant O B-Disease O B-Disease
<OOV> B-Disease I-Disease B-Disease I-Disease
of I-Disease I-Disease I-Disease I-Disease
the I-Disease I-Disease I-Disease I-Disease
liver L-Disease L-Disease I-Disease I-Disease
detected O O O O
by O O O O
computed O O O O
tomography O O O O
. O O O O
isolated O O O O
giant O B-Disease O B-Disease
<OOV> B-Disease I-Disease B-Disease I-Disease
of I-Disease I-Disease I-Disease I-Disease
the I-Disease I-Disease I-Disease I-Disease
liver L-Disease L-Disease I-Disease I-Disease
are O O O O
rare O O O O
, O O O O
and O O O O
they O O O O
are O O O O
frequently O O O O
misdiagnosed O O O O
as O O O O
primary O B-Disease O B-Disease
or O I-Disease O I-Disease
secondary O I-Disease O I-Disease
tumors U-Disease L-Disease B-Disease I-Disease
of O O O O
the O O O O
liver O O O O
. O O O O
we O O O O
describe O O O O
the O O O O
computed O O O O
tomography O O O O
findings O O O O
in O O O O
0 O O O O
patients O O O O
with O O O O
giant O B-Disease O B-Disease
<OOV> B-Disease I-Disease B-Disease I-Disease
of I-Disease I-Disease I-Disease I-Disease
the I-Disease I-Disease I-Disease I-Disease
liver L-Disease L-Disease I-Disease I-Disease
. O O O O
one O O O O
patient O O O O
had O O O O
a O O O O
large O O O O
low O O O O
- O O O O
attenuation O O O O
lesion U-Disease O B-Disease O
with O O O O
rim O O O O
enhancement O O O O
after O O O O
contrast O O O O
. O O O O
the O O O O
other O O O O
patient O O O O
had O O O O
multiple O O O O
calcific B-Disease B-Disease B-Disease B-Disease
lesions L-Disease L-Disease I-Disease I-Disease
that O O O O
did O O O O
not O O O O
enhance O O O O
but O O O O
showed O O O O
a O O O O
rim O O O O
of O O O O
hypoattenuation O O O O
after O O O O
contrast O O O O
. O O O O
biopsy O O O O
established O O O O
the O O O O
diagnosis O O O O
and O O O O
both O O O O
patients O O O O
recovered O O O O
with O O O O
antituberculous O O O O
chemotherapy O O O O
. O O O O
perinatal B-Disease O B-Disease O
cerebral I-Disease B-Disease I-Disease B-Disease
arterial I-Disease I-Disease I-Disease I-Disease
infarction L-Disease L-Disease I-Disease I-Disease
associated O O O O
with O O O O
a O O O O
placental B-Disease B-Disease B-Disease B-Disease
chorioangioma L-Disease L-Disease I-Disease I-Disease
. O O O O
placental U-Disease B-Disease B-Disease B-Disease
chorioangiomas O L-Disease O I-Disease
are O O O O
benign O B-Disease O B-Disease
vascular B-Disease I-Disease B-Disease I-Disease
tumors L-Disease L-Disease I-Disease I-Disease
. O O O O
large O O O O
chorioangiomas U-Disease O B-Disease O
cause O O O O
several O O O O
obstetric O O O O
complications O O O O
, O O O O
including O O O O
premature O B-Disease O B-Disease
labor O L-Disease O I-Disease
, O O O O
placental B-Disease B-Disease B-Disease B-Disease
abruption L-Disease L-Disease I-Disease I-Disease
, O O O O
polyhydramnios U-Disease U-Disease B-Disease B-Disease
, O O O O
fetal B-Disease B-Disease B-Disease B-Disease
hydrops L-Disease L-Disease I-Disease I-Disease
, O O O O
fetal O B-Disease O B-Disease
growth O I-Disease O I-Disease
restriction O L-Disease O I-Disease
, O O O O
fetal B-Disease B-Disease B-Disease B-Disease
hepatosplenomegaly L-Disease L-Disease I-Disease I-Disease
, O O O O
cardiomegaly U-Disease U-Disease B-Disease B-Disease
, O O O O
congestive B-Disease B-Disease B-Disease B-Disease
heart I-Disease I-Disease I-Disease I-Disease
failure L-Disease L-Disease I-Disease I-Disease
, O O O O
and O O O O
fetal B-Disease B-Disease B-Disease B-Disease
death L-Disease L-Disease I-Disease I-Disease
. O O O O
the O O O O
neonatal O B-Disease O B-Disease
complications O L-Disease O I-Disease
are O O O O
hydrops B-Disease B-Disease B-Disease B-Disease
fetalis L-Disease L-Disease I-Disease I-Disease
, O O O O
microangiopathic B-Disease B-Disease B-Disease B-Disease
hemolytic I-Disease I-Disease I-Disease I-Disease
anemia L-Disease L-Disease I-Disease I-Disease
, O O O O
and O O O O
thrombocytopenia U-Disease U-Disease B-Disease B-Disease
. O O O O
the O O O O
cause O O O O
of O O O O
perinatal B-Disease B-Disease B-Disease B-Disease
cerebral I-Disease I-Disease I-Disease I-Disease
arterial I-Disease I-Disease I-Disease I-Disease
infarction L-Disease L-Disease I-Disease I-Disease
remains O O O O
unclear O O O O
in O O O O
the O O O O
majority O O O O
of O O O O
cases O O O O
. O O O O
investigators O O O O
have O O O O
reported O O O O
a O O O O
number O O O O
of O O O O
obstetric O O O O
and O O O O
neonatal O B-Disease O B-Disease
complications O L-Disease O I-Disease
in O O O O
the O O O O
setting O O O O
of O O O O
perinatal O B-Disease O B-Disease
stroke U-Disease L-Disease B-Disease I-Disease
, O O O O
including O O O O
birth O B-Disease O B-Disease
asphyxia U-Disease L-Disease B-Disease I-Disease
, O O O O
preeclampsia U-Disease U-Disease B-Disease B-Disease
, O O O O
chorioamnionitis U-Disease U-Disease B-Disease B-Disease
, O O O O
cardiac B-Disease B-Disease B-Disease B-Disease
anomalies L-Disease L-Disease I-Disease I-Disease
, O O O O
polycythemia U-Disease U-Disease B-Disease B-Disease
, O O O O
systemic B-Disease B-Disease B-Disease B-Disease
infection L-Disease L-Disease I-Disease I-Disease
, O O O O
and O O O O
genetic O B-Disease O B-Disease
thrombophilias U-Disease L-Disease B-Disease I-Disease
. O O O O
we O O O O
present O O O O
a O O O O
rare O O O O
case O O O O
of O O O O
perinatal O B-Disease O B-Disease
cerebral B-Disease I-Disease B-Disease I-Disease
infarction L-Disease L-Disease I-Disease I-Disease
associated O O O O
with O O O O
placental B-Disease B-Disease B-Disease B-Disease
chorioangioma L-Disease L-Disease I-Disease I-Disease
. O O O O
psychophysiological O O O O
reactions O O O O
associated O O O O
with O O O O
qigong O O O O
therapy O O O O
. O O O O
qigong O O O O
as O O O O
a O O O O
part O O O O
of O O O O
the O O O O
traditional O O O O
chinese O O O O
medicine O O O O
is O O O O
similar O O O O
to O O O O
western O O O O
<OOV> O O O O
meditation O O O O
<OOV> O O O O
, O O O O
indian O O O O
<OOV> O O O O
yoga O O O O
<OOV> O O O O
or O O O O
japanese O O O O
<OOV> O O O O
zen O O O O
<OOV> O O O O
, O O O O
which O O O O
can O O O O
all O O O O
be O O O O
included O O O O
in O O O O
the O O O O
category O O O O
of O O O O
traditional O O O O
psychotherapy O O O O
. O O O O
a O O O O
series O O O O
of O O O O
physiological O O O O
and O O O O
psychological O O O O
effects O O O O
occur O O O O
in O O O O
the O O O O
course O O O O
of O O O O
qigong O O O O
training O O O O
, O O O O
but O O O O
inappropriate O O O O
training O O O O
can O O O O
lead O O O O
to O O O O
physical O O O O
and O O O O
mental O B-Disease O B-Disease
disturbances O L-Disease O I-Disease
. U-Disease O B-Disease O
physiological O O O O
effects O O O O
include O O O O
changes O O O O
in O O O O
eeg O O O O
, O O O O
emg O O O O
, O O O O
respiratory O O O O
movement O O O O
, O O O O
heart O O O O
rate O O O O
, O O O O
skin O O O O
potential O O O O
, O O O O
skin O O O O
temperature O O O O
and O O O O
finger O O O O
tip O O O O
volume O O O O
, O O O O
sympathetic O O O O
nerve O O O O
function O O O O
, O O O O
function O O O O
in O O O O
stomach O B-Disease O B-Disease
and O I-Disease O I-Disease
intestine O I-Disease O I-Disease
, O I-Disease O I-Disease
metabolism O L-Disease O I-Disease
, O O O O
endocrine O O O O
and O O O O
immunity O O O O
systems O O O O
. O O O O
psychological O O O O
effects O O O O
are O O O O
motor O O O O
phenomena O O O O
and O O O O
perceptual O O O O
changes O O O O
: O O O O
patients O O O O
experienced O O O O
<OOV> O O O O
, O O O O
<OOV> O U-Disease O B-Disease
, O O O O
itching O B-Disease O B-Disease
sensation O L-Disease O I-Disease
in O O O O
the O O O O
skin O O O O
, O O O O
numbness O U-Disease O B-Disease
, O O O O
soreness O U-Disease O B-Disease
, O O O O
<OOV> O U-Disease O B-Disease
, O O O O
relaxation O O O O
, O O O O
<OOV> O U-Disease O B-Disease
, O O O O
floating O O O O
, O O O O
dropping O O O O
, O O O O
enlargement O U-Disease O B-Disease
or O O O O
constriction O B-Disease O B-Disease
of O I-Disease O I-Disease
the O I-Disease O I-Disease
body O I-Disease O I-Disease
image O L-Disease O I-Disease
, O O O O
a O O O O
sensation O O O O
of O O O O
rising O O O O
to O O O O
the O O O O
sky O O O O
, O O O O
falling O O O O
off O O O O
, O O O O
standing O O O O
upside O O O O
down O O O O
, O O O O
playing O O O O
on O O O O
the O O O O
swing O O O O
following O O O O
respiration O O O O
, O O O O
circulation O O O O
of O O O O
the O O O O
intrinsic O O O O
qi O O O O
, O O O O
electric O O O O
shock O O O O
, O O O O
<OOV> O O O O
, O O O O
during O O O O
qigong O B-Disease O B-Disease
exercise O L-Disease O I-Disease
. O O O O
some O O O O
patients O O O O
experienced O O O O
<OOV> O O O O
illusions O O O O
, O O O O
unreality O O O O
and O O O O
<OOV> U-Disease O B-Disease O
. O O O O
these O O O O
phenomena O O O O
were O O O O
transient O O O O
and O O O O
vanished O O O O
as O O O O
the O O O O
exercise O O O O
terminated O O O O
. O O O O
qigong B-Disease O B-Disease O
deviation I-Disease O I-Disease O
syndrome L-Disease O I-Disease O
has O O O O
become O O O O
a O O O O
diagnostic O O O O
term O O O O
and O O O O
is O O O O
now O O O O
used O O O O
widely O O O O
in O O O O
china O O O O
. O O O O
antiproliferative O O O O
effects O O O O
of O O O O
homogenates O O O O
derived O O O O
from O O O O
five O O O O
strains O O O O
of O O O O
candidate O O O O
probiotic O O O O
bacteria O O O O
. O O O O
unheated O O O O
and O O O O
heat O O O O
- O O O O
treated O O O O
homogenates O O O O
were O O O O
separately O O O O
prepared O O O O
from O O O O
candidate O O O O
probiotic O O O O
bacteria O O O O
, O O O O
including O O O O
lactobacillus O O O O
rhamnosus O O O O
gg O O O O
, O O O O
bifidobacterium O O O O
lactis O O O O
, O O O O
lactobacillus O O O O
acidophilus O O O O
, O O O O
lactobacillus O O O O
delbrueckii O O O O
subsp O O O O
. O O O O
bulgaricus O O O O
, O O O O
and O O O O
streptococcus O O O O
thermophilus O O O O
. O O O O
we O O O O
compared O O O O
the O O O O
phytohemagglutinin O O O O
- O O O O
induced O O O O
proliferation O O O O
of O O O O
mononuclear O O O O
cells O O O O
in O O O O
the O O O O
presence O O O O
of O O O O
homogenates O O O O
and O O O O
in O O O O
the O O O O
presence O O O O
of O O O O
a O O O O
control O O O O
containing O O O O
no O O O O
homogenate O O O O
by O O O O
assessing O O O O
thymidine O O O O
incorporation O O O O
in O O O O
cell O O O O
cultures O O O O
. O O O O
all O O O O
homogenates O O O O
suppressed O O O O
proliferation O O O O
, O O O O
whether O O O O
the O O O O
enzymatic O O O O
activity O O O O
was O O O O
inactivated O O O O
or O O O O
not O O O O
inactivated O O O O
by O O O O
heating O O O O
. O O O O
when O O O O
the O O O O
proliferation O O O O
assays O O O O
were O O O O
repeated O O O O
with O O O O
cytoplasmic O O O O
and O O O O
cell O O O O
wall O O O O
extracts O O O O
derived O O O O
from O O O O
the O O O O
homogenate O O O O
of O O O O
l O O O O
. O O O O
rhamnosus O O O O
gg O O O O
, O O O O
the O O O O
cytoplasmic O O O O
extract O O O O
but O O O O
not O O O O
the O O O O
cell O O O O
wall O O O O
extract O O O O
was O O O O
suppressive O O O O
. O O O O
these O O O O
findings O O O O
indicate O O O O
that O O O O
candidate O O O O
probiotic O O O O
bacteria O O O O
possess O O O O
a O O O O
heat O O O O
- O O O O
stable O O O O
antiproliferative O O O O
component O O O O
( O O O O
s O O O O
) O O O O
. O O O O
these O O O O
bacteria O O O O
may O O O O
be O O O O
used O O O O
to O O O O
generate O O O O
microbiologically O O O O
nonviable O O O O
yet O O O O
immunologically O O O O
active O O O O
probiotic O O O O
food O O O O
products O O O O
that O O O O
are O O O O
easier O O O O
to O O O O
store O O O O
and O O O O
have O O O O
a O O O O
longer O O O O
shelf O O O O
life O O O O
. O O O O
transient O O O O
focal B-Disease O B-Disease O
neurological I-Disease B-Disease I-Disease B-Disease
deficit L-Disease L-Disease I-Disease I-Disease
in O O O O
sarcoidosis U-Disease U-Disease B-Disease B-Disease
. O O O O
sarcoidosis U-Disease U-Disease B-Disease B-Disease
presents O O O O
only O O O O
infrequently O O O O
with O O O O
stroke U-Disease U-Disease B-Disease B-Disease
or O O O O
focal B-Disease O B-Disease O
neurological I-Disease B-Disease I-Disease B-Disease
deficit L-Disease L-Disease I-Disease I-Disease
and O O O O
recurrent O O O O
focal B-Disease O B-Disease O
neurological I-Disease B-Disease I-Disease B-Disease
deficit L-Disease L-Disease I-Disease I-Disease
is O O O O
rarer O O O O
still O O O O
. O O O O
this O O O O
case O O O O
report O O O O
describes O O O O
a O O O O
patients O O O O
presenting O O O O
with O O O O
episodic O B-Disease O B-Disease
non O I-Disease O I-Disease
- O I-Disease O I-Disease
fluent O I-Disease O I-Disease
dysphasia U-Disease L-Disease B-Disease I-Disease
of O O O O
abrupt O O O O
onset O O O O
occurring O O O O
during O O O O
a O O O O
period O O O O
of O O O O
00 O O O O
months O O O O
without O O O O
evidence O O O O
of O O O O
seizure U-Disease B-Disease B-Disease B-Disease
activity O L-Disease O I-Disease
or O O O O
macroscopic O O O O
granulomatous O O O O
collection O O O O
. O O O O
the O O O O
case O O O O
illustrates O O O O
that O O O O
the O O O O
presentation O O O O
of O O O O
neurosarcoidosis U-Disease U-Disease B-Disease B-Disease
may O O O O
mimic O O O O
classic O O O O
reversible O O O O
ischaemic B-Disease B-Disease B-Disease B-Disease
neurological I-Disease I-Disease I-Disease I-Disease
deficit L-Disease L-Disease I-Disease I-Disease
. O O O O
disease O O O O
- O O O O
specific O O O O
questionnaire O O O O
for O O O O
patients O O O O
with O O O O
a O O O O
renal O B-Disease O B-Disease
transplant O L-Disease O I-Disease
. O O O O
a O O O O
disease O O O O
- O O O O
specific O O O O
questionnaire O O O O
to O O O O
assess O O O O
the O O O O
quality O O O O
of O O O O
life O O O O
of O O O O
renal O B-Disease O B-Disease
transplant O L-Disease O I-Disease
recipients O O O O
was O O O O
developed O O O O
. O O O O
a O O O O
list O O O O
of O O O O
items O O O O
of O O O O
potential O O O O
relevance O O O O
to O O O O
these O O O O
patients O O O O
was O O O O
created O O O O
and O O O O
00 O O O O
transplant O O O O
recipients O O O O
rated O O O O
the O O O O
importance O O O O
of O O O O
each O O O O
item O O O O
. O O O O
a O O O O
combination O O O O
of O O O O
factor O O O O
analysis O O O O
and O O O O
clinical O O O O
judgment O O O O
was O O O O
then O O O O
used O O O O
to O O O O
create O O O O
the O O O O
final O O O O
questionnaire O O O O
which O O O O
consists O O O O
of O O O O
00 O O O O
questions O O O O
in O O O O
0 O O O O
dimensions O O O O
( O O O O
physical O O O O
symptoms O O O O
, O O O O
fatigue O U-Disease O B-Disease
, O O O O
uncertainty O O O O
/ O O O O
fear O O O O
, O O O O
appearance O O O O
and O O O O
emotions O O O O
) O O O O
. O O O O
the O O O O
physical O O O O
symptoms O O O O
dimension O O O O
is O O O O
patient O O O O
specific O O O O
. O O O O
all O O O O
questions O O O O
are O O O O
scored O O O O
on O O O O
a O O O O
0 O O O O
- O O O O
point O O O O
likert O O O O
scale O O O O
. O O O O
the O O O O
reproducibility O O O O
of O O O O
the O O O O
questionnaire O O O O
when O O O O
it O O O O
was O O O O
administered O O O O
to O O O O
stable O O O O
transplant O O O O
recipients O O O O
was O O O O
high O O O O
( O O O O
intraclass O O O O
correlation O O O O
coefficients O O O O
between O O O O
0 O O O O
. O O O O
00 O O O O
and O O O O
0 O O O O
. O O O O
00 O O O O
for O O O O
the O O O O
0 O O O O
dimensions O O O O
) O O O O
. O O O O
the O O O O
scores O O O O
of O O O O
all O O O O
dimensions O O O O
except O O O O
appearance O O O O
improved O O O O
0 O O O O
months O O O O
after O O O O
transplantation O O O O
, O O O O
when O O O O
compared O O O O
to O O O O
pretransplantation O O O O
scores O O O O
. O O O O
patients O O O O
who O O O O
had O O O O
a O O O O
well O O O O
- O O O O
functioning O O O O
graft O O O O
( O O O O
creatinine O O O O
< O O O O
000 O O O O
mmol O O O O
/ O O O O
l O O O O
) O O O O
had O O O O
higher O O O O
scores O O O O
than O O O O
those O O O O
with O O O O
poorly O O O O
functioning O O O O
grafts O O O O
. O O O O
this O O O O
questionnaire O O O O
is O O O O
easy O O O O
to O O O O
administer O O O O
and O O O O
is O O O O
valid O O O O
, O O O O
reproducible O O O O
in O O O O
stable O O O O
patients O O O O
and O O O O
responsive O O O O
to O O O O
change O O O O
. O O O O
carbon O O O O
monoxide O O O O
suppresses O O O O
membrane O O O O
expression O O O O
of O O O O
<OOV> O O O O
via O O O O
myeloid O O O O
differentiation O O O O
factor O O O O
- O O O O
0 O O O O
in O O O O
<OOV> O O O O
cells O O O O
. O O O O
islet O O O O
allografts O O O O
from O O O O
donor O O O O
mice O O O O
exposed O O O O
to O O O O
co O O O O
are O O O O
protected O O O O
from O O O O
immune O B-Disease O B-Disease
rejection O L-Disease O I-Disease
after O O O O
transplantation O O O O
via O O O O
the O O O O
suppression O O O O
of O O O O
membrane O O O O
trafficking O O O O
/ O O O O
activation O O O O
of O O O O
<OOV> O O O O
in O O O O
islets O O O O
/ O O O O
beta O O O O
cells O O O O
. O O O O
the O O O O
molecular O O O O
mechanisms O O O O
of O O O O
how O O O O
co O O O O
suppresses O O O O
<OOV> O O O O
activation O O O O
in O O O O
beta O O O O
cells O O O O
remain O O O O
unclear O O O O
and O O O O
are O O O O
the O O O O
focus O O O O
of O O O O
this O O O O
study O O O O
. O O O O
cells O O O O
of O O O O
the O O O O
insulinoma U-Disease U-Disease B-Disease B-Disease
cell O O O O
line O O O O
, O O O O
<OOV> O O O O
, O O O O
were O O O O
stably O O O O
transfected O O O O
with O O O O
<OOV> O O O O
- O O O O
<OOV> O O O O
- O O O O
yfp O O O O
and O O O O
<OOV> O O O O
- O O O O
monomer O O O O
- O O O O
golgi O O O O
plasmids O O O O
and O O O O
used O O O O
to O O O O
identify O O O O
the O O O O
subcellular O O O O
distribution O O O O
of O O O O
<OOV> O O O O
before O O O O
and O O O O
after O O O O
lps O O O O
stimulation O O O O
by O O O O
confocal O O O O
microscopy O O O O
. O O O O
immunofluorescence O O O O
analysis O O O O
revealed O O O O
that O O O O
<OOV> O O O O
mainly O O O O
resides O O O O
in O O O O
the O O O O
golgi O O O O
apparatus O O O O
in O O O O
<OOV> O O O O
cells O O O O
when O O O O
in O O O O
a O O O O
quiescent O O O O
state O O O O
. O O O O
lps O O O O
stimulation O O O O
led O O O O
to O O O O
a O O O O
rapid O O O O
trafficking O O O O
of O O O O
<OOV> O O O O
from O O O O
the O O O O
golgi O O O O
to O O O O
the O O O O
cell O O O O
membrane O O O O
. O O O O
physical O O O O
interaction O O O O
between O O O O
<OOV> O O O O
and O O O O
myeloid O O O O
differentiation O O O O
factor O O O O
- O O O O
0 O O O O
( O O O O
md O O O O
- O O O O
0 O O O O
) O O O O
was O O O O
confirmed O O O O
by O O O O
immunoprecipitation O O O O
. O O O O
depleting O O O O
md O O O O
- O O O O
0 O O O O
using O O O O
small O O O O
interfering O O O O
rna O O O O
or O O O O
blocking O O O O
the O O O O
n O O O O
- O O O O
glycosylation O O O O
of O O O O
cells O O O O
using O O O O
tunicamycin O O O O
blocked O O O O
membrane O O O O
trafficking O O O O
of O O O O
<OOV> O O O O
. O O O O
pre O O O O
- O O O O
exposing O O O O
cells O O O O
to O O O O
co O O O O
at O O O O
a O O O O
concentration O O O O
of O O O O
000 O O O O
parts O O O O
per O O O O
million O O O O
suppressed O O O O
membrane O O O O
trafficking O O O O
of O O O O
<OOV> O O O O
via O O O O
inhibiting O O O O
its O O O O
glycosylation O O O O
and O O O O
the O O O O
interaction O O O O
between O O O O
<OOV> O O O O
and O O O O
md O O O O
- O O O O
0 O O O O
. O O O O
in O O O O
conclusion O O O O
, O O O O
md O O O O
- O O O O
0 O O O O
is O O O O
required O O O O
for O O O O
the O O O O
glycosylation O O O O
of O O O O
<OOV> O O O O
and O O O O
its O O O O
consequent O O O O
membrane O O O O
trafficking O O O O
in O O O O
<OOV> O O O O
cells O O O O
. O O O O
co O O O O
suppresses O O O O
membrane O O O O
activation O O O O
of O O O O
<OOV> O O O O
via O O O O
blocking O O O O
its O O O O
glycosylation O O O O
and O O O O
the O O O O
physical O O O O
interaction O O O O
between O O O O
<OOV> O O O O
and O O O O
md O O O O
- O O O O
0 O O O O
. O O O O
transvesical O O O O
endoscopic O O O O
placement O O O O
of O O O O
sutures O B-Disease O B-Disease
for O I-Disease O I-Disease
repair O I-Disease O I-Disease
of O I-Disease O I-Disease
posterior B-Disease I-Disease B-Disease I-Disease
urethral I-Disease I-Disease I-Disease I-Disease
strictures L-Disease L-Disease I-Disease I-Disease
. O O O O
reapproximation O O O O
of O O O O
urethra O B-Disease O B-Disease
or O I-Disease O I-Disease
skin O L-Disease O I-Disease
across O O O O
an O O O O
excised O B-Disease O B-Disease
scar O I-Disease O I-Disease
in O I-Disease O I-Disease
the O I-Disease O I-Disease
posterior O I-Disease O I-Disease
urethra O L-Disease O I-Disease
requires O O O O
placement O B-Disease O B-Disease
of O I-Disease O I-Disease
sutures O I-Disease O I-Disease
deep O I-Disease O I-Disease
in O I-Disease O I-Disease
the O I-Disease O I-Disease
perineum O I-Disease O I-Disease
, O I-Disease O I-Disease
across O I-Disease O I-Disease
the O I-Disease O I-Disease
external O I-Disease O I-Disease
sphincter O L-Disease O I-Disease
, O O O O
and O O O O
into O O O O
the O O O O
prostatic O B-Disease O B-Disease
urethra O L-Disease O I-Disease
itself O O O O
. O O O O
in O O O O
the O O O O
most O O O O
problematic O O O O
cases O O O O
, O O O O
placement O O O O
of O O O O
such O O O O
sutures O O O O
via O O O O
a O O O O
suprapubic O B-Disease O B-Disease
cystostomy O I-Disease O I-Disease
tract O L-Disease O I-Disease
eliminates O O O O
most O O O O
of O O O O
the O O O O
usual O O O O
difficulties O O O O
. O O O O
volatile O O O O
flavor O O O O
components O O O O
of O O O O
rice O O O O
cakes O O O O
. O O O O
volatiles O O O O
were O O O O
obtained O O O O
from O O O O
commercially O O O O
prepared O O O O
and O O O O
laboratory O O O O
- O O O O
prepared O O O O
rice O O O O
cakes O O O O
using O O O O
high O O O O
- O O O O
flow O O O O
dynamic O O O O
headspace O O O O
isolation O O O O
with O O O O
tenax O O O O
trapping O O O O
. O O O O
analysis O O O O
was O O O O
carried O O O O
out O O O O
by O O O O
capillary O O O O
gc O O O O
/ O O O O
ms U-Disease O B-Disease O
. O O O O
more O O O O
than O O O O
00 O O O O
compounds O O O O
were O O O O
identified O O O O
. O O O O
major O O O O
volatiles O O O O
included O O O O
0 O O O O
- O O O O
hydroxy O O O O
- O O O O
0 O O O O
- O O O O
<OOV> O O O O
, O O O O
furfuryl O O O O
alcohol O O O O
, O O O O
0 O O O O
, O O O O
0 O O O O
- O O O O
<OOV> O O O O
, O O O O
0 O O O O
- O O O O
<OOV> O O O O
, O O O O
pyrazine O O O O
, O O O O
hexanal O O O O
, O O O O
furfural O O O O
, O O O O
pentanol O O O O
, O O O O
0 O O O O
- O O O O
hydroxy O O O O
- O O O O
0 O O O O
- O O O O
butanone O O O O
( O O O O
acetoin O O O O
) O O O O
, O O O O
and O O O O
ethyl O O O O
- O O O O
0 O O O O
, O O O O
0 O O O O
- O O O O
<OOV> O O O O
. O O O O
although O O O O
not O O O O
ideally O O O O
applicable O O O O
to O O O O
a O O O O
dry O O O O
product O O O O
, O O O O
concentration O O O O
/ O O O O
threshold O O O O
ratios O O O O
indicated O O O O
that O O O O
the O O O O
compounds O O O O
with O O O O
a O O O O
high O O O O
probability O O O O
of O O O O
contributing O O O O
to O O O O
the O O O O
aroma O O O O
and O O O O
flavor O O O O
included O O O O
0 O O O O
- O O O O
<OOV> O O O O
, O O O O
dimethyl O O O O
trisulfide O O O O
, O O O O
0 O O O O
- O O O O
ethyl O O O O
- O O O O
0 O O O O
, O O O O
0 O O O O
- O O O O
<OOV> O O O O
, O O O O
0 O O O O
- O O O O
<OOV> O O O O
, O O O O
hexanal O O O O
, O O O O
( O O O O
e O O O O
, O O O O
e O O O O
) O O O O
- O O O O
0 O O O O
, O O O O
0 O O O O
- O O O O
<OOV> O O O O
, O O O O
0 O O O O
- O O O O
<OOV> O O O O
, O O O O
0 O O O O
- O O O O
acetyl O O O O
- O O O O
0 O O O O
- O O O O
pyrroline O O O O
, O O O O
0 O O O O
- O O O O
<OOV> O O O O
- O O O O
0 O O O O
- O O O O
ol O O O O
, O O O O
and O O O O
0 O O O O
- O O O O
<OOV> O O O O
- O O O O
0 O O O O
- O O O O
one O O O O
. O O O O

